

**CUMULATIVE
SUPPLEMENT 7**

JAN'93-JUL'93

ST. LOUIS COLLEGE OF PHARMACY LIBRARY

OCT 05 1993


APPROVED DRUG PRODUCTS

**WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS**

13TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

RM
301.45
.A66
1993
Jul
Suppl



RM301.45 .A66 1993 Jul Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

1.0 IN
1.1
1.2
1.3
1.4
1.5

2.0 D
2.1
2.2
2.3

2.4
2.5

2.6
2.7

PATENT

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Cumulative Supplement 7

JULY 1993

CONTENTS

Library Use Only

	<i>PAGE</i>
1.0 INTRODUCTION	iii
1.1 How to Use the Cumulative Supplement	iii
1.2 Products Requiring Revised Labeling for Full Approval	v
1.3 Applicant Name Changes	vi
1.4 USP Monograph Title Additions or Changes	vii
1.5 Report of Counts for the Prescription Drug Product List	ix
2.0 DRUG PRODUCT LISTS	
2.1 Prescription Drug Product List	1
2.2 OTC Drug Product List	53
2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List	55
2.4 Orphan Drug Product Designations	56
2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	60
2.6 Biopharmaceutic Guidance Availability	61
2.7 ANDA Suitability Petitions	62
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Exclusivity Terms	63
B. Patent and Exclusivity Lists	64

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

CUMULATIVE SUPPLEMENT 7

JULY 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >ADD> to the left of the line on which new information exists. The >ADD> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >DLT> (DELETE) to the left of the line containing overstruck print. The >DLT> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "⦿" symbol to designate their non-marketed status. All products having a "⦿" symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

<u>Products</u>	<u>Federal Register Reference</u>
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

AH ROBINS CO
(ROBINS)

AH ROBINS CO
(ROBINS AH)

ASTRA PHARMACEUTICAL PRODUCTS INC
(ASTRA)

ASTRA USA INC
(ASTRA)

BAKER CUMMINS PHARMACEUTICALS INC
(BAKER CUMMINS)

BAKER NORTON PHARMACEUTICALS INC
(BAKER NORTON)

BENEDICT NUCLEAR PHARMACEUTICALS INC
(BENEDICT)

NORTH AMERICAN CHEMICAL CORPORATION
(NORTH AM CHEM)

BOLAR PHARMACEUTICAL CO INC
(BOLAR)

CIRCA PHARMACEUTICALS INC
(CIRCA)

CIS US INC
(CIS)

CIS US INC
(CIS US)

CUTTER BIOLOGICAL DIV
MILES LABORATORIES INC
(CUTTER)

MILES LABORATORIES INC
(MILES LABS)

DANBURY PHARMACAL INC
(DANBURY)

DANBURY PHARMACAL INC
(DANBURY PHARMA)

FUJISAWA PHARMACEUTICAL CO
(FUJISAWA)

FUJISAWA USA INC
(FUJISAWA)

HERBERT LABORATORIES DIV
SMITH KLINE AND FRENCH CO
(HERBERT)

ALLERGAN HERBERT DIV ALLERGAN INC
(ALLERGAN HERBERT)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME
(FORMER ABBREVIATED NAME)

NEW APPLICANT NAME
(NEW ABBREVIATED NAME)

ICI PHARMACEUTICALS GROUP
DIV ICI AMERICAS
(ICI)

ZENECA PHARMACEUTICALS GROUP
(ZENECA)

LYPHOMED DIV FUJISAWA USA INC
(LYPHOMED)

FUJISAWA USA INC
(FUJISAWA)

ROXANE LABORATORIES INC
(ROXANE)

ROXANE LABORATORIES INC
(ROXANE LABS)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV MCNEILAB
(JOHNSON RW)

RW JOHNSON PHARMACEUTICAL RESEARCH
INSTITUTE DIV ORTHO PHARMACEUTICAL
CORP
(JOHNSON RW)

SCHIAPPARELLI SEARLE
(SCHIAPPARELLI SEARLE)

SCS PHARMACEUTICALS
(SCS PHARMS)

SOMERSET PHARMACEUTICALS INC
(SOMERSET)

SOMERSET PHARMACEUTICALS INC
(SOMERSET PHARMS)

STERLING DRUG INC
(STERLING)

STERLING WINTHROP INC
(STERLING WINTHROP)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE
(FORMER ADP DOSAGE FORM; ROUTE)

NEW USP MONOGRAPH TITLE
(NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF JULY 1993.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 1992</u>	<u>MAR 1993</u>	<u>JUN 1993</u>	<u>SEP 1993</u>
DRUG PRODUCTS LISTED	9488	9392	9194	
SINGLE SOURCE	2245 (23.7%)	2243 (23.9%)	2119 (23.0%)	
MULTISOURCE	7243 (76.3%)	7149 (76.1%)	7075 (77.0%)	
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6432 (68.5%)	6357 (69.1%)	
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	562 (5.9%)	555 (6.1%)	
EXCEPTIONS ¹	150 (1.6%)	155 (1.7%)	163 (1.8%)	
NEW MOLECULAR ENTITIES APPROVED	--	3	2	
NUMBER OF APPLICANTS	477	484	508	

¹Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

PRESCRIPTION DRUG PRODUCT LIST
13TH EDITION
CUMULATIVE SUPPLEMENT NUMBER 7 / JAN '93 - JUL '93

1

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOSUAN

/AB/ /MAL-LAB/

/ 32.5MG; 50MG; 40MG /

/N87628/001/

/DEC/22, 1986/

N87628 001

OCT 01, 1986

TABLET; ORAL

ESBAC

/AB/ /FOREST/PHARMS/

/ 32.5MG; 50MG; 40MG /

/N89660/001/

/DEC/22, 1986/

N89660 001

DEC 23, 1988

> DLT >
> DLT >
> ADD >
> ADD >

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

COMPAL

AA PURDUE FREDERICK

/ 356.4MG; 30MG; 16MG /

N88584 001

MAR 04, 1986

/N88584/001/

/MAR/04, 1986/

/ 356.4MG; 30MG; 16MG /

/AB/ /SOLVAY/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@ LEMMON

/ 300MG; 50MG /

N88324 001

DEC 29, 1983

/N88324/001/

/DEC/29, 1983/

/ACETAMINOPHEN/M/ /CODEINE PHOSPHATE/ / 300MG; 50MG /

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ALLAY

/AB/ /LUCHEM/

/ 500MG; 5MG /

/N89907/001/

/JAN/13, 1989/

N89907 001

JAN 13, 1989

TABLET; ORAL

ANEXSTA

AA BOEHRINGER MANNHEIM

/ 500MG; 5MG /

N89160 001

APR 23, 1987

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL

ANEXSTA

/AB/ /SKCP/

/ 500MG; 5MG /

/N89725/001/

/APR/23, 1987/

N89725 001

SEP 30, 1987

/N89725/001/

/SEP/30, 1987/

ANEXSTA 7.5/650

BOEHRINGER MANNHEIM

650MG; 7.5MG

/AB/ /SKCP/

/ 650MG; 7.5MG /

/PURADYNE, OHC/

/FOREST/PHARMS/

/ 500MG; 5MG /

@ FOREST PHARMS

500MG; 5MG

MAR 17, 1983

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AB/ /LUCHEM/

/ 500MG; 5MG /

AA NORTON HN

500MG; 5MG

/N89696/001/

/APR/21, 1988/

N89696 001

APR 21, 1988

/AB/ /MIDWEST/

/ABANA/

/ 500MG; 5MG /

/N88871/001/

/MAY/15, 1986/

N88871 001

MAY 15, 1986

@ ABANA

500MG; 5MG

/AB/ /LYDLETT/

/JOHNSON/RW/

/ 500MG; 5MG /

/N89385/001/

/AUG/27, 1986/

N89385 001

AUG 27, 1986

@ JOHNSON RM

500MG; 5MG

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN

/AB/ /HALSEY/

/ 650MG; 100MG /

@ HALSEY

650MG; 100MG

/N72106/001/

/MAY/13, 1988/

N72106 001

MAY 13, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

/ACETAZOLAMIDE SODIUM/

/AB/ /QUAD/

/EQ 500MG/VIAL/

@ QUAD

EQ 500MG/VIAL

/N89619/001/

/JAN/13, 1988/

N89619 001

JAN 13, 1988

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

DIAMOX
LEDERLE

/EQ 500MG/VIAL/

/N19383/001/
/JUL/21/1987/

EQ 500MG/VIAL

/N19388/001/
/DEC/05/1990/

>_ADD_>
>_ADD_>
>_ADD_>
>_ADD_>

TABLET, EXTENDED RELEASE; ORAL

VOLMAX

BC + MURO

EQ 4MG BASE

N19604 002
DEC 23, 1992
N19604 001
DEC 23, 1992

EQ 8MG BASE

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ZOVIRAX

+ BURROUGHS MELLICOME

EQ 1GM BASE/VIAL

N18603 002
JUN 29, 1989

CAPSULE; ORAL

AMANTADINE HCL

/N17382/001/
/JAN/21/1987/

EQ 100MG

N18603 003
AUG 30, 1983

EQ BOLAR

EQ 100MG

ALBUTEROL SULFATE

SOLUTION; INHALATION

ALBUTEROL SULFATE

AN COPLEY

EQ 0.083% BASE

N73495 001
MAY 28, 1993

SYRUP; ORAL

AMANTADINE HCL

AA MIKART

50MG/5ML

N74028 001
JUN 28, 1993

SYRUP; ORAL

ALBUTEROL SULFATE

AA WATSON LABS

EQ 2MG BASE/5ML

N73165 001
APR 29, 1993

/TABLET; ORAL/
/SYMPTREL/
/+/ DUPONT/
EQ DUPONT

100MG/100MG

/N18101/001/
N18101 001

TABLET; ORAL

ALBUTEROL SULFATE

AB NOVOPHARM

EQ 2MG BASE

N72779 001
JUN 25, 1993

INJECTABLE; INJECTION

CONACTIN/
ROCHE

EQ 250MG/VIAL

/N50565/001/
/DEC/21/1984/

EQ 4MG BASE

N72780 001
JUN 25, 1993

EQ 500MG/VIAL

/N50565/002/
/DEC/21/1984/

TABLET, EXTENDED RELEASE; ORAL

PROVENTIL

BC + SCHERING

EQ 4MG BASE

/N19383/001/
/JUL/13/1987/

EQ 250MG/VIAL

EQ 500MG/VIAL

N50565 001
DEC 21, 1984

BC SCHERING

EQ 4MG BASE

N19383 001
JUL 13, 1987

EQ 1GM/VIAL

N50565 002
DEC 21, 1984

VOLMAX

BC + SANDOZ

EQ 4MG BASE

/N19604/002/
/DEC/23/1992/

EQ 1GM/VIAL

N50565 003
DEC 21, 1984

+/

EQ 4MG BASE

/N19604/001/
/DEC/23/1992/

EQ 1GM/VIAL

N50565 003
DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN

DUPONT MERCK

> ADD > AP
> ADD >
> ADD > AP
> ADD >

EQ 50MG BASE/ML

N63350 001
JUL 30, 1993

EQ 250MG BASE/ML

N63350 002
JUL 30, 1993

/AMIKACIN/IN SODIUM CHLORIDE/0.5% IN PLASTIC CONTAINER/
/BRISTOL/
/EQ 5MG/BASE/ML/
/N50618 002/
/NOV 30, 1987/
/N50618 001/
/NOV 30, 1987/
/EQ 10MG/BASE/ML/
/N50618 002
NOV 30, 1987
/N50618 001
NOV 30, 1987

3 BRISTOL

EQ 5MG BASE/ML

3

EQ 10MG BASE/ML

AMINO ACIDS

INJECTABLE; INJECTION

NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER

BAXTER

15%

N20107 001
FEB 05, 1993

/NOVAMINE/0.5%/
/KALCIUM/

/0.5%/
/N17957 002/
/AUG 09, 1982/
/N17957 002
AUG 09, 1982

3 KABIVITRUM

TRAVASOL 10% IN PLASTIC CONTAINER

BAXTER

10%

N18931 003
AUG 23, 1984

/10%/
/N18931 004/
/APR 23, 1986/
/TRAVASOL/10% W/O ELECTROLYTES IN PLASTIC CONTAINER/
/BAXTER/
/10%/
/N18931 003/
/AUG 23, 1984/
N18931 001
AUG 23, 1984

TRAVASOL 5.5% IN PLASTIC CONTAINER

BAXTER

5.5%

/TRAVASOL/5.5% W/O ELECTROLYTES IN PLASTIC CONTAINER/
/BAXTER/
/5.5%/
/N18931 001/
/AUG 23, 1984/
TRAVASOL 8.5% IN PLASTIC CONTAINER

BAXTER

8.5%

/TRAVASOL/8.5% W/O ELECTROLYTES IN PLASTIC CONTAINER/
/BAXTER/
/8.5%/
/N18931 002
AUG 23, 1984
/N18931 001/
/AUG 23, 1984/
INJECTABLE; INJECTION
AMINOPHYLLINE
/BRISTOL/
FUJISAMA

/AP/
AP

3

25MG/ML
25MG/ML

/N87431 001/
N88407 001
JAN 25, 1984
N87431 001

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE;
POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION

/AMINOSIN/11/7% W/O ELECTROLYTES/
/ABBOTT/
/5.5% 30MG/100ML; 9.7MG/100ML; 1.20MG/100ML;
/APR 03, 1986/
/N19437 006/
/APR 03, 1986/
7% 102MG/100ML; 4.5MG/100ML
522MG/100ML; 4.10MG/100ML
N19437 006
APR 03, 1986

3 ABBOTT

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM
CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION

/AMINOSIN/11/3.5% W/
/ABBOTT/
/3.5% 30MG/100ML; 9.7MG/100ML; 1.20MG/100ML;
/APR 03, 1986/
/N19437 007/
/APR 03, 1986/
3.5% 30MG/100ML; 9.7MG/100ML;
1.20MG/100ML; 4.9MG/100ML
N19437 007
APR 03, 1986

3 ABBOTT

AMINOCAPROIC ACID

INJECTABLE; INJECTION

AMINOCAPROIC ACID

/AP/
/LYPHOMED/
/250MG/ML/
250MG/ML

3 LYPHOMED

/N170522 001/
/JUN 17, 1986/
N170522 001
JUN 17, 1986

AMINOPHYLLINE

/ENEMA/RECTAL/
/SOMOPHYLLIN/
/FISONS/
/300MG/5ML/
300MG/5ML

3 FISONS

/N18232 001/
/APR 02, 1982/
N18232 001
APR 02, 1982

INJECTABLE; INJECTION

25MG/ML
25MG/ML

/N87431 001/
N88407 001
JAN 25, 1984
N87431 001

AMINOPHYLLINE

INJECTABLE; INJECTION

AMINOPHYLLINE

/AB/ /L'YPHONED/

/15MG/ML/

/N85501/001/
/JAN/25./1984/

TABLET; ORAL

AMINOPHYLLINE

> DLT > /AB/ /SEARLE/

> ADD > /AB/ /SEARLE/

> ADD > /AB/ /SEARLE/

> ADD > /AB/ /SEARLE/

/100MG/

/200MG/

100MG

200MG

/N02386/002/
/N02386/003/
N02386 002

N02386 003

AMINOPHYLLINE

> DLT > /AB/ /ROXANE/

> ADD > AB + ROXANE

> ADD > AB + ROXANE

> DLT > /AB/

> DLT > /AB/

> ADD > AB +

> ADD > AB +

/100MG/

100MG

/200MG/

200MG

/N87500/001/
/FEB/09./1982/

N87500 001

FEB 09, 1982

/N87501/001/
/FEB/09./1982/

N87501 001

FEB 09, 1982

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION

ELAVIL

/AP/ /MSD/

AP ZENECA

/10MG/ML/

10MG/ML

/N12704/001/
N12704 001

N12704 001

TABLET; ORAL

ELAVIL

/AB/ /MSD/

/AB/ /MSD/

/AB/ /MSD/

/AB/ /MSD/

/AB/ /MSD/

/AB/ /MSD/

AB ZENECA

AB +

AB +

AB +

AB +

AB +

AB +

/10MG/

25MG

50MG

75MG

100MG

150MG

10MG

25MG

50MG

75MG

100MG

150MG

/N12703/001/
/N12703/003/
/N12703/004/
/N12703/005/
/N12703/006/
/N12703/007/

N12703 001

N12703 003

N12703 004

N12703 005

N12703 006

N12703 007

AMOXICILLIN

CAPSULE; ORAL

TRIMOX

/AB/ /SCOTTB/

/AB/ /SCOTTB/

/AB/ /SCOTTB/

/AB/ /SCOTTB/

3 APOTHECON

3

3

3

3

/150MG/

/250MG/

/500MG/

/500MG/

250MG

250MG

500MG

500MG

/N62098/001/
/N62152/001/
/N62098/002/
/N62152/002/
N62098 001
N62152 001
N62098 002
N62152 002

POWDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB CLONMEL

AB

AB

/BX/

/BX/

125MG/5ML

250MG/5ML

125MG/5ML

250MG/5ML

N62927 001
NOV 25, 1988
N62927 002
NOV 25, 1988
/N62927/001/
/NOV/25./1988/
/N62927/002/
/NOV/25./1988/

TRIMOX

/AB/ /SCOTTB/

/AB/ /SCOTTB/

/AB/ /SCOTTB/

/AB/ /SCOTTB/

3 APOTHECON

3

3

3

/125MG/5ML/

/250MG/5ML/

/125MG/5ML/

/250MG/5ML/

125MG/5ML

125MG/5ML

250MG/5ML

250MG/5ML

/N62099/001/
/N62154/001/
/N62099/002/
/N62154/002/
N62099 001
N62154 001
N62099 002
N62154 002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

CAPSULE; ORAL

DELCORSE

/LEMMON/

3

3

3

3

1.25MG; 1.25MG; 1.25MG; 1.25MG;

1.25MG

2.5MG; 2.5MG; 2.5MG; 2.5MG;

3.75MG; 3.75MG; 3.75MG;

5MG; 5MG; 5MG; 5MG;

1.25MG

2.5MG; 2.5MG; 2.5MG; 2.5MG;

3.75MG; 3.75MG; 3.75MG;

5MG; 5MG; 5MG; 5MG;

/N83564/001/
/N83564/002/
/N83564/003/
/N83564/004/
N83564 001
N83564 002
N83564 003
N83564 004

AMPICILLIN/AMPCILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

AB / AB / AB
/ PRINCIPEN '250/
/ 300TBB /

/EQ 250MG BASE/5ML/
/EQ 250MG BASE/5ML/
/EQ 250MG BASE/5ML/
/EQ 250MG BASE/5ML/
EQ 250MG BASE/5ML

/N60121/001/
/N62151/002/
N60127 001
N62151 002

> DLT >
> DLT >
> ADD >

/INJECTABLE; INJECTION/
/M.V.C. 2*3 /
/ASTRA /

100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL
15MG/VIAL; 5UGM/VIAL; 0.4MG/VIAL;
40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL;
3MG/VIAL; 1MG/VIAL;
10MG/VIAL
N18933 002
AUG 08, 1985

AMPICILLIN/AMPCILLIN TRIHYDRATE; PROBENECID

/CAPSULE; ORAL/
/PRINCIPEN W/ PROBENECID/
/300TBB /

/EQ 389MG BASE; 111MG/
/EQ 389MG BASE; 111MG/
/EQ 389MG BASE; 111MG/
EQ 389MG BASE; 111MG

/N50488/001/
/N62150/001/
N50488 001
N62150 001

ANISOTROPINE METHYLBROMIDE

/TABLETS; ORAL/
/VALFIN/50/
/DUPONT /
& DUPONT

/50MG/
50MG

/N13428/001/
N13428 001

/AB / /LYPHOMED/

INJECTABLE; INJECTION
M.V.C. 2*3
FUJISAWA

10MG/ML; 0.006MG/ML; 0.5UGM/ML;
1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML;
0.4MG/ML; 0.36MG/ML; 0.3MG/ML;
330 UNITS/ML; 1 IU/ML
N18440 002
AUG 08, 1985

/10MG/ML; 0.006MG/ML; 0.5UGM/ML;
/1.5MG/ML; 20 IU/ML; 0.04MG/ML; 4MG/ML;
/0.4MG/ML; 0.36MG/ML; 0.3MG/ML;
/330 UNITS/ML; 1 IU/ML /
/N18440/002 /
/AUG/08./1985/

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

IOPIDINE
+ ALCON

EQ 0.5% BASE

N20258 001
JUL 30, 1993

ASPIRIN; BUTALBITAL

TABLETS; ORAL
AXOTAL
/+/APR/A/

/650MG; 50MG/

+ SAVAGE

650MG; 50MG

/N88305/001/
/OCT/13./1983/
N88305 001
OCT 13, 1983

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL;
ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE;
RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

/INJECTABLE; INJECTION/
/M.V.C. 2*3 /
/ASTRA /

/100MG/VIAL; 0.06MG/VIAL; 0.005MG/VIAL/
/15MG/VIAL; 5UGM/VIAL; 0.4MG/VIAL/
/40MG/VIAL; 4MG/VIAL; 3.6MG/VIAL/
/3MG/VIAL; 1MG/VIAL;
/10MG/VIAL /

> DLT >
> DLT >

N73475 001
MAR 30, 1993
N73476 001
MAR 30, 1993

50MG
100MG

TABLETS; ORAL
ATENOLOL
MUTUAL PHARM

AB AB

ATENOLOL

TABLET; ORAL
ATENOLOL
 NOVOPHARM

AB 50MG N73315 001
 MAY 28, 1993
 AB 100MG N73316 001
 MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB 50MG;25MG N73581 001
 APR 29, 1993
 AB 100MG;25MG N73582 001
 APR 29, 1993

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
AZATHIOPRINE

/AB/ /QUAD/ /EQ 100MG BASE/VIAL/ N171056/001/
 JUN 08, 1988
 @ QUAD N71056 001
 JUN 08, 1988

/AB/ /BURROUGHS/NELLCONE/ /EQ 100MG BASE/VIAL/ N17391/001/
 BURROUGHS WELLCOME EQ 100MG BASE/VIAL N17391 001

AZLOICILLIN SODIUM

INJECTABLE; INJECTION
 AZLIN
MILES

@ MILES /EQ 2GM BASE/VIAL/ N62388 001
 SEP 08, 1982
 @ /EQ 2GM BASE/VIAL/ N62417 001
 OCT 12, 1982
 @ /EQ 4GM BASE/VIAL/ N62388/003/
 SEP 08, 1982
 @ 4GM BASE/VIAL N62388 003
 SEP 08, 1982
 @ /EQ 4GM BASE/VIAL/ N62417/003/
 OCT 12, 1982
 @ 4GM BASE/VIAL N62417 003
 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION
 AZACTAM IN PLASTIC CONTAINER
SQUIBB

@ SQUIBB 10MG/ML

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

ointment; OPHTHALMIC

CORTISPORIN

/AT/ /BURROUGHS/NELLCONE/ /500 UNITS/GM; EQ 3.5MG BASE/GM; /N50416/002/
 + BURROUGHS WELLCOME 400 UNITS/GM; EQ 3.5MG BASE/GM; N50416 002
 /ZINC BACITRACIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE; /10,000 UNITS/GM; EQ 3.5MG BASE/GM; /N62389/001/
 /HYDROCORTISONE/ /PHARMAFAIR/ /10,000 UNITS/GM; EQ 3.5MG BASE/GM; /N62389/001/
 @ PHARMAFAIR 400 UNITS/GM; EQ 3.5MG BASE/GM; N62389 001
 10,000 UNITS/GM; EQ 3.5MG BASE/GM; N62389 001
 JUL 02, 1982

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OPHTHALMIC
BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE
 /AD/ /PHARMATAIR/ /400 UNITS/GM;EQ 3.5MG BASE/GM; /N62386/001/
 /10,000 UNITS/GM/ /SEP/88,1988/
 @ PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM; N62386 001
 10,000 UNITS/GM SEP 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN
 /PHARMADERM/ /400 UNITS/GM;EQ 3.5MG BASE/GM; /N62167/001/
 /5,000 UNITS/GM/ /N62167/001/
 @ PHARMADERM 400 UNITS/GM;EQ 3.5MG BASE/GM; N62167 001
 5,000 UNITS/GM

BENTIRIOMIDE

SOLUTION; ORAL
 CHYMEX
 /ADRIA/ /500MG/7.5ML/
 SAVAGE 500MG/7.5ML
 /N18366/001/
 /DEC/28,1990/
 N18366 001
 DEC 29, 1983

BENTONITE; SULFUR

> DLT >
 > DLT >
 > DLT >
 > ADD >
 /POWDER;TOPICAL/
 /BENSULFID/
 /POYTHRESS/
 @ POYTHRESS /66.64%;33.32%/
 66.64%;33.32%
 /N02918/001/
 N02918 001

BENZONATATE

CAPSULE; ORAL
BENZONATATE
 AA PHARMACAPS 100MG N81297 001
 JAN 29, 1993
 AA IESSALON 100MG N11210 001
 FOREST LABS

BENZTHIAZIDE

TABLET; ORAL
 /ADJUTAG/
 /SOLVAY/ @ 50MG /N16001/002/
 N16001 002

BENZTHIAZIDE

TABLET; ORAL
 EXNA
 /BP/;/ROBINS/AH/ /50MG/
 + ROBINS AH 50MG
 /N12489/001/
 N12489 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL
 /AB/ /BEPATH/ /200MG/
 /MALLACE/ /300MG/
 /AB/ /400MG/
 @ WALLACE 200MG
 @ 300MG
 @ 400MG

VASCOR

/AB/ /JOHNSON/RM/ /200MG/
 /AB/ /300MG/
 /AB/;/ /400MG/
 + JOHNSON RM 400MG
 200MG
 300MG
 /N19002/001/
 /DEC/28,1990/
 N19002 001
 /N19002/002/
 /DEC/28,1990/
 N19002 002
 /N19002/003/
 /DEC/28,1990/
 N19002 003
 DEC 28, 1990

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL
BETAMETHASONE DIPROPIONATE
 /AB/ /PHARMADERM/ /EQ 0.05% BASE/
 @ PHARMADERM EQ 0.05% BASE

/N19136/001/
 /JUN/26,1984/
 N19136 001
 JUN 26, 1984

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL
BETAMETHASONE DIPROPIONATE
 /AB/ /PHARMADERM/ /EQ 0.1% BASE/

/N7664/001/
 /AUG/31/1983/
 N70274 001
 AUG 12, 1985

10MG;6.25MG
 2.5MG;6.25MG
 5MG;6.25MG

TABLET; ORAL
 ZIAC
 + LEDERLE

N20186 002
 MAR 26, 1993
 N20186 003
 MAR 26, 1993
 N20186 001
 MAR 26, 1993

ointment; TOPICAL

BETAMETHASONE DIPROPIONATE
 /AB/ /PHARMADERM/ /EQ 0.1% BASE/

/N19140/001/
 /SEP/04/1984/
 N19140 001
 SEP 04, 1984

BROMPHENIRAMINE MALEATE

TABLET; ORAL

/AA/ BROMPHENIRAMINE MALEATE /4MG/
 /ANABOLICS/ 4MG
 @ ANABOLICS /4MG/
 /AA/ /NENTRON/ 4MG
 @ NENTRON 4MG
 NYLOX TRADING 4MG
 /AA/ /TALICAPS/ 4MG
 /AA/ /ZENITH/ 4MG
 @ ZENITH 4MG

/N86187/001/
 N86187 001
 /N86987/001/
 N86987 001
 N85592 001
 /N85592/001/
 /N84351/001/
 N84351 001

BETAMETHASONE VALERATE

CREAM; TOPICAL
BETAMETHASONE VALERATE
 /AB/ /PHARMADERM/ /EQ 0.1% BASE/

/N18860/002/
 /AUG/31/1983/
 N18860 002
 AUG 31, 1983

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL

CALDEROL 0.05MG
 + ORGANON 0.02MG
 /:/JUPJOHN/ /0.05MG/
 /0.02MG/

N18312 002
 N18312 001
 /N18312/002/
 /N18312/001/

LOTION; TOPICAL
BETAMETHASONE VALERATE
 /AB/ /PHARMADERM/ /EQ 0.1% BASE/

/N18870/001/
 /AUG/31/1983/
 N18870 001
 AUG 31, 1983

ointment; TOPICAL

BETAMETHASONE VALERATE
 AB NMC EQ 0.1% BASE

N70051 001
 OCT 10, 1984

CALCITONIN, SALMON

INJECTABLE; INJECTION

/AB/ CALCITONIN /100 IU/ML/
 /AP/ + /RHONE/POULENC/RORER/ /200 IU/ML/
 MIACALCIN 200 IU/ML
 /SANDOZ/ /100 IU/ML/
 @ SANDOZ 100 IU/ML

/N17769/001/
 N17769 001

/N18864/001/
 /AUG/31/1983/
 N18864 001
 AUG 31, 1983

/N17668/001/
 /JUL/03/1986/
 N17808 001
 JUL 03, 1986

/VALIAC/
 /NMC/ /EQ 0.1% BASE/

/N70051/001/
 /OCT/10/1984/

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION
ENDOSOL EXTRA
 ALLERGAN

AT
 /AT/
 0.154MG/ML; 0.92MG/ML; 0.184MG/ML;
 0.2MG/ML; 0.38MG/ML; 2.1MG/ML;
 7.14MG/ML; 0.42MG/ML
 N20079 001
 NOV 27, 1991

ENDOSOL PLUS
 ALLERGAN/
 /AT/

0.154MG/ML; 0.92MG/ML; 0.184MG/ML;
 0.2MG/ML; 0.38MG/ML; 2.1MG/ML;
 7.14MG/ML; 0.42MG/ML
 N20079 001
 NOV 27, 1991

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
 ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER
 MCGAW

37MG/100ML; 5GM/100ML; 31MG/100ML;
 120MG/100ML; 330MG/100ML;
 88MG/100ML
 N19864 001
 JUN 10, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION
CALCIUM GLUCEPTATE

> DLT > /AP/ /ABBOTT/
 > ADD > + ABBOTT
 > DLT > /AP/ /LILLY/
 > ADD > @ LILLY
 /AP/ /LYPHOMED/
 @ LYPHOMED
 /EQ 90MG CALCIUM/5ML / N80001 001 / N80001 001
 /EQ 90MG CALCIUM/5ML / N06470 001 / N06470 001
 /EQ 90MG CALCIUM/5ML / N89373 001 / N89373 001
 /APR /30 /1987 /
 APR 30, 1987

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN
 /AP/ /ROERIG/
 /AP/ /ROERIG/
 /AP/ /ROERIG/
 /AP/ /ROERIG/

/EQ 1GM BASE/VIAL / N50306 001 / N50306 001
 /EQ 2GM BASE/VIAL / N50306 004 / N50306 004
 /EQ 5GM BASE/VIAL / N50306 002 / N50306 002
 /EQ 10GM BASE/VIAL / N50306 006 / N50306 006

PYOPEN

/AP/ /SMITHKLINE BEECHAM/
 /AP/ /SMITHKLINE BEECHAM/
 /AP/ /SMITHKLINE BEECHAM/
 /AP/ /SMITHKLINE BEECHAM/

/EQ 1GM BASE/VIAL / N50298 001 / N50298 001
 /EQ 2GM BASE/VIAL / N50298 002 / N50298 002
 /EQ 5GM BASE/VIAL / N50298 003 / N50298 003
 /EQ 10GM BASE/VIAL / N50298 006 / N50298 006
 /EQ 20GM BASE/VIAL / N50298 007 / N50298 007

CARBINOXAMINE MALEATE

/TABLET/ /ORAL /
 /CLISTIN /
 /JOHNSON/RM /
 @ JOHNSON RM

/4MG /
 4MG
 / N08915 001 /
 N08915 001

CARISOPRODOL

/CAPSULE/ /ORAL /
 /SONA /
 /MALLACE /
 @ WALLACE

/250MG /
 250MG
 / N11792 003 /
 N11792 003

TABLET; ORAL

CARTISOPRODOL

/AB/ /PIONEER/PHARMS/
 @ PIONEER PHARMS

/350MG /
 350MG
 / N89390 001 /
 N89390 001
 OCT 13, 1988

/RELA /

/SCHERING /
 @ SCHERING

/350MG /
 350MG
 / N12155 001 /
 N12155 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
OPTIPRESS
/BURROUENS/MELLICOME/ /L:/
OTSUKA

/N19972/001/
/MAY/23/1990/
N19972 001
MAY 23, 1990

> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> ADD > + ZENECA
> ADD > +
> ADD >
> ADD >

/N50588/001/
/DEC/27/1985/
/N50588/002/
/DEC/27/1985/
/N50588/001/
/APR/29/1993/
/N50588/002/
/APR/29/1993/
N50588 001
DEC 27, 1985
N50588 002
DEC 27, 1985
N63293 001
APR 29, 1993
N63293 002
APR 29, 1993
N50694 002
JUL 30, 1993
N50694 001
JUL 30, 1993

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION
MANDOL
+ LILLY

N50504 004

> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> ADD > + ZENECA
> ADD > +
> ADD >
> ADD >

DEC 27, 1985
N50588 002
DEC 27, 1985
N63293 001
APR 29, 1993
N63293 002
APR 29, 1993
N50694 002
JUL 30, 1993
N50694 001
JUL 30, 1993

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE; INJECTION/
/CEFMAX/
/TAKEDA/

/N50571/001/
/DEC/30/1987/
/N50571/002/
/DEC/30/1987/
/N50571/003/
/DEC/30/1987/
N50571 001
DEC 30, 1987
N50571 002
DEC 30, 1987
N50571 003
DEC 30, 1987

> DLT > /AP/ /EQ 500MG BASE/VIAL/
> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> ADD > + ZENECA
> ADD > +
> ADD >
> ADD >

DEC 27, 1985
N50588 002
DEC 27, 1985
N63293 001
APR 29, 1993
N63293 002
APR 29, 1993
N50694 002
JUL 30, 1993
N50694 001
JUL 30, 1993

3 TAP

3

3

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID
SMITHKLINE BEECHAM

N63295 001
JUL 26, 1993
/N50579/003/
/MAY/23/1984/
N50579 003
MAY 23, 1984

> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> ADD > + ZENECA
> ADD > +
> ADD >
> ADD >

DEC 27, 1985
N50588 002
DEC 27, 1985
N63293 001
APR 29, 1993
N63293 002
APR 29, 1993
N50694 002
JUL 30, 1993
N50694 001
JUL 30, 1993

3

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER
MERCK

> DLT > /AP/ /EQ 1GM BASE/VIAL/
> DLT > /AP/ /EQ 2GM BASE/VIAL/
> ADD > + ZENECA
> ADD > +
> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

DEC 27, 1985
N50588 002
DEC 27, 1985
N63293 001
APR 29, 1993
N63293 002
APR 29, 1993
N50694 002
JUL 30, 1993
N50694 001
JUL 30, 1993

N63182 001
JAN 25, 1993
N63182 002
JAN 25, 1993

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
/CEFTAZIDIME SODIUM/
/AYERST AYERST/

/EQ 1GM BASE/VIAL/

/N50633/002/
/JAN 31, 1989/

/EQ 2GM BASE/VIAL/

/N50633/003/
/JAN 31, 1989/

/EQ 10GM BASE/VIAL/

/N50633/005/
/JAN 31, 1989/

EQ 1GM BASE/VIAL

3 MYETH AYERST

EQ 2GM BASE/VIAL

3

EQ 10GM BASE/VIAL

3

KEFUROX

LILLY

ZINACEF

GLAXO

INJECTABLE; INJECTION

SEFUROXIME

MARSAM

AP

EQ 750MG BASE/VIAL

N64035 001
FEB 26, 1993

AP

EQ 1.5GM BASE/VIAL

N64035 002
FEB 26, 1993

AP

EQ 7.5GM BASE/VIAL

N64036 001
FEB 26, 1993

EQ 7.5GM BASE/VIAL

N62591 003
DEC 17, 1987

EQ 7.5GM BASE/VIAL

N50558 004
OCT 23, 1986

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION

CEFTAZIDIME SODIUM IN PLASTIC CONTAINER

AP BAXTER

EQ 10MG BASE/ML

N63221 001
APR 29, 1993

AP

EQ 20MG BASE/ML

N63221 002
APR 29, 1993

AP

EQ 40MG BASE/ML

N63221 003
APR 29, 1993

FORTAZ IN PLASTIC CONTAINER

AP GLAXO

EQ 10MG BASE/ML

N50634 001
APR 28, 1989

AP

EQ 20MG BASE/ML

N50634 002
APR 28, 1989

AP

EQ 40MG BASE/ML

N50634 003
APR 28, 1989

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL

CALCIBIND

/MISSION PHARMA/

/2.5GM PACKET/

2.5GM/PACKET

N18757 002
DEC 28, 1982

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

/LYPHOMED/

AP

/EQ 500MG BASE/VIAL/

N62723 001
NOV 17, 1986

AP

/EQ 1GM BASE/VIAL/

N62723 002
NOV 17, 1986

AP

/EQ 2GM BASE/VIAL/

N62723 003
NOV 17, 1986

AP

/EQ 4GM BASE/VIAL/

N62723 004
NOV 17, 1986

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION

CEFTIZOX

FUJISAWA

EQ 10GM BASE/VIAL

N50560 005
MAR 19, 1993

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEPHAPIRIN SODIUM

/LYPHOMED/

AP

/EQ 500MG BASE/VIAL/

N62723 001
NOV 17, 1986

AP

/EQ 1GM BASE/VIAL/

N62723 002
NOV 17, 1986

AP

/EQ 2GM BASE/VIAL/

N62723 003
NOV 17, 1986

AP

/EQ 4GM BASE/VIAL/

N62723 004
NOV 17, 1986

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER

/ROCHE/

N50624 001
FEB 11, 1987

3 ROCHE

EQ 10MG BASE/ML

3 LYPHOMED

EQ 500MG BASE/VIAL

N62723 001
NOV 17, 1986

3

EQ 1GM BASE/VIAL

N62723 002
NOV 17, 1986

3

EQ 2GM BASE/VIAL

N62723 003
NOV 17, 1986

3

EQ 4GM BASE/VIAL

N62723 004
NOV 17, 1986

CHLORDIAZEPOXIDE

/CAPSULE, EXTENDED/RELEASE, ORAL/
 /LIBRELESE/
 /+/ROCHE/
 @ ROCHE 30MG
 /30MG/
 30MG
 /N17813/001/
 /SEP/12, 1983/
 N17813 001
 SEP 12, 1983

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
 /AB/ /PIONEER/PHARMS/ /25MG/
 @ PIONEER PHARMS 25MG
 /5MG/
 /10MG/
 /25MG/
 /25MG/
 /25MG/
 /5MG
 @ ROCHE
 @
 @
 @

/N89558/001/
 /JUL/15, 1988/
 N89558 001
 JUL 15, 1988
 /N12249/002/
 /N12249/001/
 /N12249/003/
 /N85475/001/
 N85475 001
 N12249 002
 N12249 001
 N12249 003

/LIBROUM
 /ROCHE/
 /+/

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
ALDOCLOR-150
 /AB/ /MSD/ /150MG; 250MG/
 MSD
ALDOCLOR-250
 /AB/ /+/ /MSD/ /250MG; 250MG/
 + MSD
METHYLDOPA AND CHLOROTHIAZIDE
 /AB/ /PAR/ /150MG; 250MG/
 /250MG; 250MG/
 @ PAR 150MG; 250MG
 @ 250MG; 250MG

/N16016/001/
 N16016 001
 /N16016/002/
 N16016 002
 /N70783/001/
 /NOV/06, 1987/
 /N70654/001/
 /NOV/06, 1987/
 N70783 001
 NOV 06, 1987
 N70654 001
 NOV 06, 1987

CHLOROTRIANISENE

CAPSULE; ORAL
 TACE
 /MERRILL/DOW/
 @ MERRILL DOW

/72MG/
 72MG

/N16235/001/
 N16235 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION

CHLORPHENIRAMINE MALEATE

/AB/ /BEL/MAR/ /10MG/ML/
 @ BEL MAR 10MG/ML
 /AB/ /STERIS/
 STERIS /100MG/ML/
 /100MG/ML
 /AB/ /STERIS/ /100MG/ML/
 @ BEL MAR 100MG/ML

/N86821/001/
 N80821 001
 /N86821/001/
 N86095 001
 /N83733/001/
 N83733 001

TABLET; ORAL

CHLORPHENIRAMINE MALEATE

/AB/ /NEUTRON/
 @ NEUTRON /4MG/
 4MG

/N86519/001/
 N86519 001

CHLORPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

CHLORPROMAZINE HCL

/AB/ /LYPHOMED/
 @ LYPHOMED /25MG/ML/
 25MG/ML

/N84911/001/
 N84911 001

CHLORTHALIDONE

TABLET; ORAL

CHLORTHALIDONE

/AB/ /PHARM/BASICS/
 @ PHARM BASICS /50MG/
 50MG

/N89052/001/
 /JUN/01, 1987/
 N89052 001
 JUN 01, 1987

CHLORTHALIDONE; METOPROLOL TARTRATE

/CAPSULE, ORAL/
 /LOPRESSIDONE/
 /+/CIBA/

/25MG; 200MG/
 /25MG; 200MG/

/N19451/001/
 /DEC/31, 1987/
 /N19451/001/
 /DEC/31, 1987/

CHLOROTHALIDONE; METOPROLOL TARTRATE

CAPSULE; ORAL
LOPRESSIDONE

25MG;100MG
25MG;200MG
a
a

N19451 001
DEC 31, 1987
N19451 002
DEC 31, 1987

CAPSULE; ORAL

CLEOCIN

AB + UPJOHN
/AB//+/
AB +
/AB//+/
a
a

EQ 75MG BASE
/EQ 75MG BASE/
EQ 150MG BASE
/EQ 150MG BASE/
EQ 75MG BASE
EQ 150MG BASE

N50162 001
/N61809/001/
N50162 002
/N61809/002/
N61809 001
N61809 002

CHLORZOXAZONE

TABLET; ORAL

CHLORZOXAZONE

/AA/ /PIONEER/PHARMS/

/AA/ /500MG/
/500MG/

/N89592/001/
/JAN/06/1989/
/N89948/001/
/JAN/06/1989/

a PIONEER PHARMS
a

N89592 001
JAN 06, 1989
N89948 001
JAN 06, 1989

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION

CLEOCIN PHOSPHATE

AP + UPJOHN

/AP/ /CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%
/L-YPHOMED/

EQ 150MG BASE/ML
EQ 150MG BASE/ML
EQ 12MG BASE/ML

N50441 001
/N50636/001/
/DEC/22/1989/
N50636 001
DEC 22, 1989

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC

CATARASE

+ IOLAB

300 UNITS/VIAL
/150/UNITS/VIAL/
150 UNITS/VIAL
/300/UNITS/VIAL/

N16938 001
/N18121/001/
N18121 001
/N16938/001/

TABLET; ORAL

CLONIDINE HCL

/AB/ /BIOCRAFT/
/AB/ /BIOCRAFT/
/AB/ /BIOCRAFT/

/0.1MG/
/0.2MG/
/0.3MG/

/N7074/001/
/MAR/20/1986/
/N70702/001/
/MAR/20/1986/
/N70659/001/
/MAR/20/1986/
N70747 001
JUL 08, 1986
N70702 001
JUL 08, 1986
N70659 001
JUL 08, 1986

> ADD > CISAPRIDE MONOHYDRATE

TABLET; ORAL

PROPULSID

+ JANSSEN

EQ 20MG BASE
EQ 10MG BASE

N20210 002
JUL 29, 1993
N20210 001
JUL 29, 1993

CLADRIBINE

INJECTABLE; INJECTION

LEUSTATIN

+ JOHNSON RW

1MG/ML

/CREAM; VAGINAL/
/SYNE-LO TRIMIN/
/BT/ /SCHERING/
/MYCELEX-S/
/BT/ /NILES/
/BT/ /NILES/

/N18052/001/
/N18230/001/

CLOTIRIMAZOLE

/TABLET;/VAGINAL/
/SYNE-LOTRIMIN/
/BT/
/SICHERING/
/NYCELEX-6/
/MILLES/

/100MG/
/100MG/

/SOLUTION;/NASAL/
/NASALCROM/
/FISONS/

/4%/
/N18306/001/
/MAR/18./1983/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE M/ CODEINE

> ADD > AA 10MG/5ML; 5.25MG/5ML
> ADD > PENNEX PHARMS
> DLT > /AA/ /PHARM/BASICS/
> DLT > /100MG/5ML; 5.25MG/5ML/

SPRAY, METERED; NASAL
NASALCROM
+ FISONS

5.2MG/INH
N18306 001
MAR 18, 1983

CORTICOTROPIN

INJECTABLE; INJECTION

ACTHAR

/AP/
/AP/
AP
AP
/45 UNITS/VIAL/
/40 UNITS/VIAL/
25 UNITS/VIAL
40 UNITS/VIAL

H. P. ACTHAR GEL

/BC/
/BC/;
BC
BC +
/BC/
/BC/
a
a

/40 UNITS/ML/
/80 UNITS/ML/
40 UNITS/ML
80 UNITS/ML
/40 UNITS/ML/
/80 UNITS/ML/
40 UNITS/ML
80 UNITS/ML

/N07504/002/
/N07504/003/
N07504 002
N07504 003

/N08372/006/
/N08372/008/
N08372 006
N08372 008
/N08975/001/
/N08975/002/
N08975 001
N08975 002

/AP/
/AP/
/AP/
/AP/
/AP/
/AP/

CYANOCOBALAMIN

INJECTABLE; INJECTION

CYANOCOBALAMIN

/AP/
/DELL/
DELL
/FUJISAMA/
a FUJISAMA
/RUBIVITTE/
/BEL/MAR/

/N80669/001/
N80689 001
/N83075/001/
N83075 001

/AP/
/AP/
/AP/
/AP/
/AP/

/N10791/004/
/N10791/002/
/N10791/003/
/N10791/001/
/N10791/005/
N10791 004
N10791 001
N10791 002
N10791 005
N10791 003

a BEL MAR

a

a

a

CYCLACILLIN

/POWDER/FOR/RECONSTITUTION;/ORAL/

/CYCLAPEN-M/
/MYETH/AYERST/

/500MG/5ML/
/250MG/5ML/
/250MG/5ML/
125MG/5ML
250MG/5ML
500MG/5ML

/N50508/001/
/N50508/002/
/N50508/003/
N50508 001
N50508 002
N50508 003

a WYETH AYERST

a

a

CORTICOTROPIN-ZINC HYDROXIDE

INJECTABLE; INJECTION

CORTICOTROPIN-ZINC

/a
/a
/40 UNITS/ML/
40 UNITS/ML

/N09854/001/
N09854 001

CORTISONE ACETATE

TABLET; ORAL

CORTISONE ACETATE

/BP/
/HEATHER/
a HEATHER

/N85736/001/
N85736 001

CYCLIZINE LACTATE

INJECTABLE; INJECTION

MAPEZINE

/BURROUGHS/MELLICOME/
a BURROUGHS MELLICOME

/50MG/ML/
50MG/ML
/N09495/001/
N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL

CYCLOBENZAPRINE HCL

AB INVANED

10MG

N73683 001
FEB 26, 1993

SPRAY, METERED; NASAL
DDAVP

RHONE POULENC RORER

0.01MG/INH
N17922 002
FEB 06, 1989

DESMOPRESSIN ACETATE

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION

NEOSAR

AP ADRIA

100MG/VIAL

N40015 001
APR 29, 1993

200MG/VIAL

N40015 002
APR 29, 1993

500MG/VIAL

N40015 003
APR 29, 1993

1GM/VIAL

N40015 004
APR 29, 1993

2GM/VIAL

N40015 005
APR 29, 1993

DESOXYCORTICOSTERONE PIVALATE

INJECTABLE; INJECTION
PERCORTEN

/CIBA/
@ CIBA

/25MG/ML/
25MG/ML

/N08822/001/
N08822 001

DEXAMETHASONE

ELIXIR; ORAL

DEXAMETHASONE

AA BARRE

0.5MG/5ML

N88997 001
OCT 10, 1986

/AA/ /NASKA/

/0.5MG/5ML/

/N88997/001/
/001/001/1986/

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HCL

/MYLAN/
@ MYLAN

/4MG/
4MG

/N86678/001/
N86678 001

SOLUTION; ORAL
DEXAMETHASONE

/ROXANE/

/0.5MG/5ML/

/N88248/001/
/SEP/01/1983/

@ ROXANE

0.5MG/5ML

SEP 01, 1983

DESIPRAMINE HYDROCHLORIDE

CAPSULE; ORAL

PERTOFRANE

+ /RHONE POULENC RORER

/50MG/
/25MG/
25MG

@ RHONE POULENC RORER

50MG

/N13621/001/
/N13621/001/
N13621 001

TABLET; ORAL

DECADRON

MSD

+

0.5MG

0.75MG

1.5MG

4MG

/0.5MG/
/0.75MG/
/1.5MG/
/4MG/

N11664 001

N11664 002

N11664 003

N11664 005

/N11664/001/
/N11664/002/
/N11664/003/
/N11664/005/

N11664 001

N84611 001

N84613 001

N84610 001

N84612 001

/N84611/001/
/N84613/001/
/N84610/001/
/N84612/001/

N84611 001

N84613 001

N84610 001

N84612 001

DESLANOSIDE

INJECTABLE; INJECTION

SEDILANTID

/SANDOZ/
@ SANDOZ

/0.2MG/ML/
0.2MG/ML

/N09282/002/
N09282 002

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OPHTHALMIC

/AT/ /PHARMAFAIR/ /0.1% EQ 3.5MG BASE/GM; /N62411/001/ /10,000 UNITS/GM/ /MAY 16, 1983/

PHARMAFAIR

SUSPENSION/DROPS; OPHTHALMIC

/AT/ /PHARMAFAIR/ /0.1% EQ 3.5MG BASE/ML; /N62428/001/ /10,000 UNITS/ML/ /MAY 18, 1983/

PHARMAFAIR

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

/AP/ /BELMAR/ /EQ 4MG PHOSPHATE/ML; /N84752/001/ /BEL MAR/ /EQ 4MG PHOSPHATE/ML/ /N84752/001/ /AP/ /FUJISAWA/ /EQ 4MG PHOSPHATE/ML; /N87065/001/ /FUJISAWA/ /EQ 4MG PHOSPHATE/ML/ /N87065/001/ /AP/ /ORGANON/ /EQ 20MG PHOSPHATE/ML; /N14694/004/ /ORGANON/ /EQ 20MG PHOSPHATE/ML/ /N14694/004/

a ORGANON
 a ORGANON

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL

/AA/ /LEMON/ /5MG/ /N83735/001/ /AA/ /LEMON/ /5MG/ /N83735/001/ /BB/ /LEMON/ /10MG/ /N83735/002/ /BB/ /FERNDALE/ /5MG/ /N84001/001/ /BB/ /FERNDALE/ /5MG/ /N84001/001/

a LEMON
 a LEMON
 a FERNDEX/
 a FERNDALE/
 a FERNDALE

DEXTROSE

INJECTABLE; INJECTION

/AP/ /ABBOTT/ /500MG/ML; /N19445/001/ /AP/ /ABBOTT/ /500MG/ML; /N19445/001/ /JUN 03, 1986/

ABBOTT

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION

/MCGAM/ /ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER; /N19873/001/ /26MG/100ML; 320MG/100ML/ /MCGAM/ /ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER; /N19873/001/ /26MG/100ML; 320MG/100ML/ /JUN 10, 1993/

MCGAM

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

/MCGAM/ /ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER; /N19844/001/ /220MG/100ML; 140MG/100ML/ /MCGAM/ /ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER; /N19844/001/ /220MG/100ML; 140MG/100ML/ /JUN 10, 1993/

MCGAM

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

/MCGAM/ /ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER; /N19870/001/ /280MG/100ML; 91MG/100ML/ /MCGAM/ /ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER; /N19870/001/ /280MG/100ML; 91MG/100ML/ /JUN 10, 1993/

MCGAM

DIATRIZOATE MEGUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/STERLING/ /HYPAQUE-N, 75%; /50%; 25%/ /STERLING/ /HYPAQUE-N, 90%; /60%; 30%/ /STERLING/ /HYPAQUE-N, 90%; /60%; 30%/

a STERLING
 a STERLING
 a STERLING

DIATRIZOATE SODIUM

/SOLUTION; HETERAN/
/HYPAQUE/SODIUM/20%/
/STERLING/
@ STERLING

/20%/
20%
/N09561/001/
N09561 002

DIAXOXIDE
CAPSULE; ORAL
PROGLYCEM
+ BAKER NORTON
/:/MEDIC/MKTS/

50MG
/50MG/
/N17425 001/
/N17425/001/

DIAZEPAM

INJECTABLE; INJECTION

AP DIAZEPAM
MARSAM

5MG/ML

N72370 001
JAN 29, 1993

5MG/ML

N72371 001
JAN 29, 1993

5MG/ML

N72397 001
JAN 29, 1993

AP VALIUM
/ROCHE/
AP + ROCHE

/5MG/ML/
5MG/ML

/N16087/001/
N16087 001

INJECTABLE; INTRAVENOUS
DIZAC

+ KABI

5MG/ML

N19287 001
JUN 18, 1993

TABLET; ORAL

DIAZEPAM

@ FERNDALE

2MG

N70903 001
APR 01, 1987

5MG

N70904 001
APR 01, 1987

10MG

N70905 001
APR 01, 1987

/AB/ /PHARM/PASTIS/

/2MG/

/N70903/001/
/APR/01, 1987/

/AB/

/5MG/

/N70904/001/
/APR/01, 1987/

/AB/

/10MG/

/N70905/001/
/APR/01, 1987/

/AB/ /ZENITH/

/2MG/

/N70360/001/
/SEP/04, 1985/

/AB/

/5MG/

/N70361/001/
/SEP/04, 1985/

@ ZENITH

2MG

N70360 001
SEP 04, 1985

@

5MG

N70361 001
SEP 04, 1985

DIAZOXIDE

INJECTABLE; INJECTION
/AB/ /DIAZOXIDE/
/QUAD/

/15MG/ML/
15MG/ML

/N71908/001/
/JAN/26, 1988/
N71908 001
JAN 26, 1988

AP HYPERSTAT
/SCHERING/
SCHERING

/15MG/ML/
15MG/ML

/N16996/001/
N16996 001

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC
VOLTAREN
/CIBA/

/0.1%/
0.1%

/N20037/001/
/MAR/28, 1991/
N20037 001
MAR 28, 1991

CIBA VISION

0.1%

DICUMAROL

TABLET; ORAL

DICUMAROL

/:/ABBOTT/
@ ABBOTT

/50MG/
50MG

/N05545/004/
N05545 004

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

DICYCLOMINE HCL
/PIONEER/PHARMS/

/10MG/
10MG

/N89361/001/
/JAN/10, 1989/
N89361 001
JAN 10, 1989

@ PIONEER PHARMS

10MG

TABLET; ORAL

DICYCLOMINE HCL
/PIONEER/PHARMS/

/20MG/
20MG

/N88585/001/
/AUG/20, 1986/
N88585 001
AUG 20, 1986

@ PIONEER PHARMS

20MG

DIETHYLSTILBESTROL

/ANJECTABLE; INJECTION/
/STILBESTROL/
/SQUIBB/

/0.2MG/ML/
/0.5MG/ML/
/1MG/ML/
/5MG/ML/
@ SQUIBB
@
@
@

/N04056/003/
/N04056/004/
/N04056/005/
/N04056/006/
N04056 003
N04056 004
N04056 005
N04056 006

N74051 001
MAR 31, 1993
N74051 002
MAR 31, 1993
N74051 003
MAR 31, 1993
N74051 004
MAR 31, 1993

30MG
60MG
90MG
120MG

TABLET; ORAL
DILTIAZEM HCL
APOTHECON

/SUPPOSITORY; NASAL/
/STILBESTROL/
/SQUIBB/
@
@

/0.1MG/
/0.5MG/
0.1MG
0.5MG

/N04056/001/
/N04056/002/
N04056 001
N04056 002

/N85874/001/
/N85874/002/
N85874 001
N85874 002

25MG
50MG

DIPHENHYDRAMINE HYDROCHLORIDE
CAPSULE; ORAL
DIPHENHYDRAMINE HCL
/LEMMON/
@
@

TABLET, DELAYED RELEASE; ORAL
STILBETIN
/SQUIBB/
@ SQUIBB

/0.1MG/
0.1MG

/N04056/011/
N04056 011

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL
/BEL MAR/
@ BEL MAR
/PRISTOL/
@ FUJISAWA

10MG/ML
10MG/ML
10MG/ML

/N80822/001/
N80822 001
/N87066/001/
N87066 001

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD
BC + CARDERM

180MG
240MG
120MG
300MG

N20062 002
DEC 27, 1991
N20062 003
DEC 27, 1991
N20062 001
AUG 10, 1992
N20062 004
DEC 27, 1991

DIPHENYLPYRALINE HYDROCHLORIDE

/CAPSULE; EXTENDED RELEASE; ORAL/
/HISPRIL/
/+//SMITHKLINE/BEECHAM/ 5MG/
@ SMITHKLINE BEECHAM 5MG

/N11945/001/
N11945 001

/BC/+//MARION/MERRELL/PDOW/ 180MG/
/BC/+// 240MG/
/+// 120MG/
/+// 300MG/
/+//

N20062 002
DEC 27, 1991
/DEC/27/1991/
/N20062/003/
/DEC/27/1991/
/N20062/001/
/AUG/10/1992/
/N20062/004/
/DEC/27/1991/

DIVALPROEX SODIUM

/TABLET; DELAYED RELEASE; ORAL/
/DEPAKOTE/CP/
/ABBOTT/
@ ABBOTT
@

EQ 250MG BASE
EQ 500MG BASE

/N19794/001/
JUL 11, 1990
/N19794/002/
/JUL/11/1990/
N19794 001
JUL 11, 1990
N19794 002
JUL 11, 1990

/EQ/250MG/BASE/
/EQ/500MG/BASE/

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

/BRISTOL/

/40MG/ML/

/N18549/001/
/MAR/11, 1983/

⊖ FUJISAWA

40MG/ML

/N18549 001

/LYPHOMED/

/40MG/ML/

/N170012/001/
/JUN/12, 1985/

⊖ LYPHOMED

40MG/ML

/N70012 001
/JUN 12, 1985

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE MONOHYDRATE

/MEDICOPHARM/

/EQ 100MG BASE/

/N50641/001/
/DEC/29, 1989/

+ VINTAGE

EQ 100MG BASE

/N50641 001
DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/PAR/

/EQ 50MG BASE/

/N62434/001/
/OCT/19, 1984/

⊖ PAR

EQ 50MG BASE

/N62434 001
OCT 19, 1984

⊖

EQ 100MG BASE

/N62442 001
DEC 22, 1983

TABLET; ORAL

DOXYCYCLINE HYCLATE

/HEATHER/

/EQ 100MG BASE/

/N62462/001/
/MAY/11, 1983/

⊖ HEATHER

EQ 100MG BASE

/N62462 001
MAY 11, 1983

PROPERIDOL

INJECTABLE; INJECTION

PROPERIDOL

/QUAD/

/2.5MG/ML/

/N17194/001/
/AUG/17, 1988/

⊖ QUAD

2.5MG/ML

/N17194 001
AUG 17, 1988

/SOLOPAK/

/2.5MG/ML/

/N171754/001/
/SEP/06, 1988/

⊖ SOLOPAK

2.5MG/ML

/N171754 001
SEP 06, 1988

⊖

2.5MG/ML

/N171754 001
SEP 06, 1988

⊖

2.5MG/ML

/N171754 001
SEP 06, 1988

EDETATE DISODIUM

INJECTABLE; INJECTION

DISODIUM EDETATE

/STERIS/

/150MG/ML/

/N84356/001/
/NOV/28, 1990/

⊖ STERIS

150MG/ML

/N84356 001
NOV 28, 1990

EFLORNITHINE HYDROCHLORIDE

INJECTABLE; INJECTION

ORNITHINE

/MERRELL/DOW/

/200MG/ML/

/N19879/002/
/NOV/28, 1989/

⊖ MERRELL DOW

200MG/ML

/N19879 002
NOV 28, 1989

ENCAINIDE HYDROCHLORIDE

CAPSULE; ORAL

ENCAID

/BRISTOL/

/50MG/

/N18981/002/
/DEC/24, 1986/

⊖ BRISTOL

50MG

/N18981 002
DEC 24, 1986

⊖ BRISTOL

50MG

/N18981 002
DEC 24, 1986

⊖

35MG

/N18981 003
DEC 24, 1986

⊖

50MG

/N18981 004
DEC 24, 1986

ENOXACIN

TABLET; ORAL
PENITREX

/S/ /PARKÉ/DAVIS/

/400MG/

/N19616/005/
/DEC/31/1991/

/200MG/

/N19616/004/
/DEC/31/1991/

+ RHONE POULENC RORER 400MG

N19616 005

200MG

DEC 31, 1991

DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; INJECTION

LOVENOX

RHONE POULENC RORER 30MG/0.3ML

N20164 001

MAR 29, 1993

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL AND EPINEPHRINE

AP STERLING WINTHROP 0.01MG/ML; 2%

N40057 002

FEB 26, 1993

FEB 26, 1993

AP LIDOCAINE HCL W/ EPINEPHRINE

/AP/ /BEL/MAR/

/0.01MG/ML; 2%/
/0.01MG/ML; 2%/
/0.01MG/ML; 1%/
/0.01MG/ML; 2%/
0.01MG/ML; 2%

0.01MG/ML; 1%
0.01MG/ML; 2%

0.01MG/ML; 2%

0.01MG/ML; 2%

EPINEPHRINE; PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL W/ EPINEPHRINE

/AP/ /BEL/MAR/

/0.02MG/ML; 1%/
/0.02MG/ML; 2%/
/0.02MG/ML; 1%/
/0.02MG/ML; 2%/
0.02MG/ML; 1%
0.02MG/ML; 2%

0.02MG/ML; 1%

0.02MG/ML; 2%

ERGOLOID MESYLATES

TABLET; ORAL

HYDERGINE

/SANDOZ/

0.5MG

/N17993/003/

N17993 003

ERGOLOID MESYLATES

TABLET; SUBLINGUAL

HYDROGENATED ERGOT ALKALOIDS

/AA/ /ZENITH/

0.5MG/

0.5MG/

/N87186/001/
N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL

ERGOMAR

/AA/ /FISON/

2MG/

2MG

/N87693/001/
/FEB/24/1983/
N87693 001

FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

ERYC/SPTAINLES/

/S/ /FAULDING/

125MG/

125MG

/N50593/001/
/JUL/22/1985/
N50593 001

JUL 22, 1985

GEL; TOPICAL

ERYGEL

/AT/ /HERBERT/

2%

2%

2%

2%

2%

2%

2%

N63211 001

JAN 29, 1993

OINTMENT; OPHTHALMIC

ERYTHROMYCIN

/AT/ /PHARMADERM/

5MG/GM

5MG/GM

5MG/GM

5MG/GM

5MG/GM

5MG/GM

/N62446/001/
/SEP/26/1983/
N62446 001

SEP 26, 1983

APR 05, 1984

ERYTHROMYCIN

/POWDER / FOR / RX / COMPOUNDS /
/ERYTHROMYCIN /
/PADDOCK /

/ 1.0% /
100%
2%
2%
/ 1.2% /
/ 1.2% /

& PADDOCK
SOLUTION; TOPICAL
ERYTHRA-DEMY
PADDOCK
ERYTHROMYCIN
BARRE
/ NASKA /
/ 1.2% /
/ 1.2% /
PADDOCK /

> ADD >
> ADD >
> ADD >
> ADD >

/ N50610 001 /
/ NOV 07, 1986 /
/ N50610 001 /
/ NOV 07, 1986 /
/ N62687 001 /
/ FEB 05, 1988 /
/ N62957 001 /
/ JUL 21, 1988 /
/ N62957 001 /
/ JUL 21, 1988 /
/ N62687 001 /
/ FEB 05, 1988 /

EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE
GENSIA
/ LYPHONED /
LYPHONED
a

ERYTHROMYCIN LACTOBIONATE
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL

N63253 001
JUL 30, 1993
N63253 002
JUL 30, 1993
/ N62604 001 /
/ NOV 24, 1986 /
/ N62604 001 /
/ NOV 24, 1986 /
/ N62604 001 /
/ NOV 24, 1986 /
N62604 001
NOV 24, 1986
N62604 002
NOV 24, 1986

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC
+ ANAQUEST
+
/ 1.0MG/ML /
/ 2.50MG/ML /

10MG/ML
250MG/ML
1.0MG/ML
2.50MG/ML

INJECTABLE; INJECTION
BREVIBLOC
+ ANAQUEST
+
/ 1.0MG/ML /
/ 2.50MG/ML /

N19386 001
AUG 15, 1988
N19386 002
DEC 31, 1986
/ N19386 001 /
/ AUG 15, 1988 /
/ N19386 002 /
/ DEC 31, 1986 /

10MG/ML
250MG/ML
1.0MG/ML
2.50MG/ML

INJECTABLE; INJECTION
BREVIBLOC
+ ANAQUEST
+
/ 1.0MG/ML /
/ 2.50MG/ML /

ERYTHROMYCIN LACTOBIONATE
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL
EQ 500MG BASE/VIAL
EQ 1GM BASE/VIAL

N19386 001
AUG 15, 1988
N19386 002
DEC 31, 1986
/ N19386 001 /
/ AUG 15, 1988 /
/ N19386 002 /
/ DEC 31, 1986 /

ESTRADIOL

TABLET; ORAL
ESTRACE
BRISTOL MYERS SQUIBB 0.5MG

BRISTOL MYERS SQUIBB 0.5MG

TABLET; ORAL
ESTRACE
BRISTOL MYERS SQUIBB 0.5MG

N81295 001
JUN 30, 1993

BRISTOL MYERS SQUIBB 0.5MG

TABLET; ORAL
ESTRACE
BRISTOL MYERS SQUIBB 0.5MG

BRISTOL MYERS SQUIBB 0.5MG

N81295 001
JUN 30, 1993

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN
+ AYERST
/ 0.625MG/GM /
/ 0.625MG/GM /

0.625MG/GM
0.625MG/GM

CREAM; TOPICAL, VAGINAL
PREMARIN
+ AYERST
/ 0.625MG/GM /
/ 0.625MG/GM /

N20216 001
/ N62623 001 /

0.625MG/GM
0.625MG/GM

CREAM; TOPICAL, VAGINAL
PREMARIN
+ AYERST
/ 0.625MG/GM /
/ 0.625MG/GM /

0.625MG/GM
0.625MG/GM

N20216 001
/ N62623 001 /

ESTROGENS, CONJUGATED

TABLET; ORAL
PREMARIN
+ MYETH AYERST

/+/
1.25MG
/1.25MG/
/1.25MG/
2.5MG

N04782 001
/N04782/002/
/N04782/001/
N04782 002

ETHYNYDIOL DIACETATE; MESTRANOL

/TABLET; ORAL-21/
/OVULEN-21/
/+ /SEARLE/
@ SEARLE

/1MG; 0.1MG/
1MG; 0.1MG

/N16705/003/
N16029 003

ESTROPIPATE

TABLET; ORAL

OGEN 3.25

+/+ /ABBOTT/
ABBOTT

OGEN 2.5

+ ABBOTT

> DLT > /AB /+ /ABBOTT/
> ADD > AB
> ADD > 3MG
> DLT > /3MG/

/N83220/002/
N83220 002

N83220 003
/N83220/003/

/TABLET; ORAL-28/
/OVULEN-28/
/SEARLE/
@ SEARLE

/1MG; 0.1MG/
1MG; 0.1MG

/N16705/001/
N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
+ MGI

50MG/ML

N19545 001
APR 20, 1987
/N19545/001/
/APR/20/1987/

/P/AND/5/

/50MG/ML/

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

AB ROBERTS

0.035MG; 1MG

/AB/ /SCHLAPPARELLI/SEARLE/0.035MG; 1MG/

N71480 001
APR 12, 1988
/N71480/001/
/APR/12/1988/

> ADD > FELBAMATE

> ADD > SUSPENSION; ORAL

> ADD > FELBATOL

> ADD > + WALLACE

> ADD >

600MG/5ML

N20189 003
JUL 29, 1993

TABLET; ORAL-28

NORETHIN 1/35E-28

AB ROBERTS

0.035MG; 1MG

/AB/ /SCHLAPPARELLI/SEARLE/0.035MG; 1MG/

N71481 001
APR 12, 1988
/N71481/001/
/APR/12/1988/

> ADD >

> ADD > TABLET; ORAL

> ADD > FELBATOL

> ADD > + WALLACE

> ADD >

> ADD >

600MG

N20189 002
JUL 29, 1993

ETHOSUXIMIDE

SYRUP; ORAL

ETHOSUXIMIDE

COPLY

ZARONTEN

PARKE DAVIS

250MG/5ML

N81306 001
JUL 30, 1993

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

/PHARMADERM/

@ PHARMADERM

@

/0.012/

/0.0125/

/N88047/001/
/DEC/16/1982/
/N88045/001/
/DEC/16/1982/
N88047 001

0.01%

DEC 16, 1982
N88045 001

0.025%

DEC 16, 1982
N88045 001

FLUOCINOLONE ACETONIDE

ointment; topical

FLUOCINOLONE ACETONIDE

/AT/ /PHARMADERM/ /0.025%/
 @ PHARMADERM 0.025%

/N88046/001/
 /DEC 16, 1982/
 N88046 001
 DEC 16, 1982

TABLET; ORAL

FUROSEMIDE

/AB/ /PARKE/DAVIS/
 /AB/ /40MG/
 /AB/ /80MG/

/N18419/001/
 /JAN 31, 1983/
 /N18419/002/
 /JAN 31, 1983/
 /N18419/003/
 /NOV 13, 1984/
 N18419 001
 JAN 31, 1983
 N18419 002
 JAN 31, 1983
 N18419 003
 NOV 13, 1984

FLUOROURACIL

injectable; injection

FLUOROURACIL

/AB/ /MARCHAR/
 @ MARCHAR 50MG/ML

/N87791/001/
 /JAN 18, 1983/
 N87791 001
 JAN 18, 1983

@ WARNER CHILCOTT

@
 @
 @

20MG
 40MG
 80MG

FLUOXETINE HYDROCHLORIDE

capsule; oral

PROZAC

LILLY

EQ 10MG BASE

N18936 006
 DEC 23, 1992

injectable; injection

OMNISCAN

STERLING WINTHROP

287MG/ML

N20123 001
 JAN 08, 1993

FLUPHENAZINE HYDROCHLORIDE

elixir; oral

FLUPHENAZINE HCL

COPLY

2.5MG/5ML

N81310 001
 APR 29, 1993

capsule; oral

GEMFIBROZIL

AB MYLAN

300MG

N73466 001
 JAN 25, 1993
 N72929 001
 JAN 29, 1993

PROLOXIN

SQUITBB

2.5MG/5ML

N12145 003

LOPID

AB + PARKE DAVIS

300MG

N18422 002

/TABLET; EXTENDED/RELEASE;/ORAL/
 /PHARMADERM/
 @ SCHERING

1MG/
 1MG

/N12419/004/
 N12419 004

GENTAMICIN SULFATE

cream; topical

GENTAMICIN SULFATE

/AT/ /PHARMADERM/

/EQ 1MG BASE/GM/

/N62530/001/
 /JUL 05, 1984/
 N62530 001
 JUL 05, 1984

FOLIC ACID

TABLET; ORAL

FOLIC ACID

/AB/ /PIONEER/PHARMS/

1MG

/N88949/001/
 /SEP 13, 1985/
 N88949 001
 SEP 13, 1985

ointment; ophthalmic

GENTAFAIR

/AT/ /PHARMAFAIR/

/EQ 3MG BASE/GM/

/N62443/001/
 /MAY 26, 1983/
 N62443 001
 MAY 26, 1983

@ PHARMAFAIR

EQ 3MG BASE/GM

GLIPIZIDE

TABLET; ORAL
GLUCOTROL
+ PFIZER

10MG
2.5MG
5MG
/1.5MG/
/5MG/

/+/ROFERS/

N17783 002
MAY 08, 1984
N17783 003
MAY 11, 1993
N17783 001
MAY 08, 1984
/N17783/002/
/MAY/08,1984/
/N17783/001/
/MAY/08,1984/

TABLET; ORAL
GLYNASE
/BX/ /UPJOHN/
/BX/+/
+ UPJOHN

/1.5MG/
/3MG/
3MG
1.5MG

/N20051/001/
/MAR/04,1992/
/N20051/002/
/MAR/04,1992/
N20051 002
MAR 04, 1992
N20051 001
MAR 04, 1992

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION

GLUCAGON
/DEL/ /LILLY/
LILLY
/DEL/ /QUAD/
@ QUAD

/EQ 1MG BASE/VIAL/
EQ 1MG BASE/VIAL
/EQ 1MG BASE/VIAL/
EQ 1MG BASE/VIAL

/N12122/001/
N12122 001
/N17022/001/
/MAR/04,1987/
N71022 001
MAR 04, 1987

INJECTABLE; INJECTION
LUTREPULSE KIT
+ FERRING
+

0.8MG/VIAL
3.2MG/VIAL
/0.8MG/VIAL/
/3.2MG/VIAL/

N19687 001
OCT 10, 1989
N19687 002
OCT 10, 1989
/N19687/001/
/OCT/10,1989/
/N19687/002/
/OCT/10,1989/

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE/PUMP/KIT/
/FERRING/
/LUTREPULSE/PUMP/KIT/
/FERRING/
@

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN
/DEL/ /DEL/NAP/
AP @ BEL MAR
/DEL/ /DEL/
AP @

/N69519/001/
/N69519/001/

/5,000 UNITS/VIAL/
5,000 UNITS/VIAL
/10,000 UNITS/VIAL/
10,000 UNITS/VIAL

/N17054/001/
N17054 001
/N17054/002/
N17054 002

GLUTETHIMIDE

CAPSULE; ORAL

DORIDEN
/S/RHONE/PDULCINE/RODER/500MG/

/N69519/001/
/N69519/001/

GLYBURIDE

TABLET; ORAL

GLYBURIDE
/BX/ /HOECHST/ROUSSEL/
/BX/ /HOECHST/ROUSSEL/

/1.5MG/
/3MG/
1.5MG
3MG

/N20055/001/
/APR/17,1992/
/N20055/002/
/APR/17,1992/
N20055 001
APR 17, 1992
N20055 002
APR 17, 1992

IMPLANT; IMPLANTATION

ZOLADEX
/+/IMPERIAL/CHEM/
+ ZENECA

/EQ 3.6MG/BASE/
EQ 3.6MG BASE

/N19726/001/
/DEC/29,1989/
N19726 001
DEC 29, 1989

>DLT>
>DLT>
>ADD>
>ADD>

GRISOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL
 GRISACTIN
 /MYETH/AYERST/
 @ MYETH AYERST
 /125MG/
 125MG
 /N50051/002/
 N50051 002

HEXACHLOROPHENE

AEROSOL; TOPICAL
 /TURGÉN/
 @ XTTRIUM/
 @ XTTRIUM
 /3%/
 3%
 /N17411/001/
 N17411 001

HALOFANTRINE HYDROCHLORIDE

TABLETS; ORAL/
 /HALFAN/
 /SMITHKLINE/BECHAM/
 @ SMITHKLINE BECHAM
 250MG
 /250MG/
 250MG
 /N20250/001/
 /JUL/24/1992/
 N20250 001
 JUL 24, 1992

EMULSION; TOPICAL

/AT/
 /HEXACHLOROPHENE/
 /HUNTINGTON/
 @ HUNTINGTON
 /3%/
 3%
 /N17411/001/
 N17411 001

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
 HALOPERIDOL
 PHARM ASSOC
 AA
 EQ 2MG BASE/ML
 /N73037/001/
 N73037 001
 FEB 26, 1993

SOLUTIONS; TOPICAL

/AT/
 /HEXACHLOROPHENE/
 /HUNTINGTON/
 @ HUNTINGTON
 /0.25%/
 0.25%
 /N17421/002/
 N17421 002

INJECTABLE; INJECTION

HALOPERIDOL
 MARSAM
 AP
 EQ 5MG BASE/ML
 /N72516/001/
 N72516 001
 FEB 25, 1993

HALOPERIDOL

AP
 EQ 5MG BASE/ML
 /N72517/001/
 N72517 001
 FEB 25, 1993

SMITH/NEPHEM SOLUTION; EQ 5MG BASE/ML

/AP/
 /SMITH/NEPHEM SOLUTION/
 EQ 5MG BASE/ML
 /DEC/14/1987/
 N70864/001
 N70864 001
 DEC 14, 1987

SOLOPAK

AP
 EQ 5MG BASE/ML
 /N70801/001/
 N70801 001
 DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION
 LIQUAMIN SODIUM
 /PREANON/
 @ ORGANON
 @
 /40,000 UNITS/ML/
 /40,000 UNITS/ML/
 40,000 UNITS/ML
 /N00552/001/
 N00552 001
 N00552 002

HEXAFLUORENIUM BROMIDE

/AT/
 /HEXAFLUORENIUM BROMIDE/
 /HUNTINGTON/
 @ HUNTINGTON
 /30MG/
 30MG
 /N17413/001/
 N17413 001

INJECTABLE; INJECTION

/MALLACE/
 @ MALLACE
 /20MG/ML/
 20MG/ML
 /N09789/003/
 N09789 003

/N16375/001/
 N16375 001
 /N17411/001/
 N17411 001
 /N08402/001/
 N08402 001
 /N19055/001/
 /NOV/30/1984/
 N19055 001
 NOV 30, 1984
 /N17421/002/
 N17421 002
 /N17412/001/
 N17412 001
 /N17412/002/
 N17412 002
 /N18363/001/
 N18363 001
 /N17446/001/
 N17446 001
 /N17413/001/
 N17413 001

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION
HISTAMINE PHOSPHATE

/LILLY/
@ LILLY
@
@
@

/EQ 0.1MG/BASE/ML/
EQ 0.1MG BASE/ML
/EQ 0.2MG/BASE/ML/
EQ 0.2MG BASE/ML
/EQ 1MG/BASE/ML/
EQ 1MG BASE/ML

/AB/
/AB/
/AB/
@ GLAXO
@
@

TABLET; ORAL
/TRANSDATE HCT/
/GLAXO/

/N19174/001/
/APR 10, 1987/
/N19174/002/
/APR 10, 1987/
/N19174/003/
/APR 10, 1987/
N19174 001
APR 10, 1987
N19174 002
APR 10, 1987
N19174 003
APR 10, 1987

/2.5MG;100MG/
/2.5MG;200MG/
/2.5MG;300MG/
25MG;100MG
25MG;200MG
25MG;300MG

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL/
SERPASIL-PRESOLINE/
/CIBA/
@ CIBA
@

/50MG;0.2MG/
/25MG;0.1MG/
50MG;0.2MG

/N09296/001/
/N09296/002/
/N09296/004/
N09296 001
N09296 002

HYDROCHLOROTHIAZIDE; LISINAPRIL

TABLET; ORAL

ZESTORETIC 20/12.5
/IMPERIAL/CHEM/

/AB/
AB ZENECA

/N19888/001/
/SEP 20, 1990/
N19888 001
SEP 20, 1990

/12.5MG;20MG/
12.5MG;20MG

HYDROCHLOROTHIAZIDE

TABLET; ORAL
HYDROCHLOROTHIAZIDE

/INWOOD/
@ INWOOD
@
/LEMMON/
@ LEMMON

/25MG/
/50MG/
25MG
50MG
/50MG/
50MG

/N84776/001/
/N84776/002/
N84776 001
N84776 002
/N86923/001/
/FEB 07, 1985/
N86923 001
FEB 07, 1985

/AB/
AB ZENECA

ZESTORETIC 20/25
/IMPERIAL/CHEM/
/25MG;20MG/
25MG;20MG

> DLT >
> DLT >
> ADD >
> ADD >

/N19888/002/
/JUL 20, 1989/
N19888 002
JUL 20, 1989

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL
NORMOZIDE

/SCHERING/
/AB/
/AB//+/
+ SCHERING

/25MG;100MG/
/25MG;200MG/
/25MG;300MG/
25MG;300MG
25MG;100MG
25MG;200MG

/N19046/001/
/APR 06, 1987/
/N19046/002/
/APR 06, 1987/
/N19046/003/
/APR 06, 1987/
N19046 001
APR 06, 1987
N19046 002
APR 06, 1987

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE
/UPSHER/SMITH/
@ UPSHER SMITH

/25MG;25MG/
25MG;25MG

/N87553/001/
N87553 001

HYDROCORTISONE

CREAM; TOPICAL
HYDROCORTISONE
BARRE

2.5%

N89682 001
MAR 10, 1988
/N89682/002/
/N89682/003/
/N89682/004/
N89682 001
MAR 10, 1988
N89682 002
N89682 003
N89682 004

2.5%

/BIOCRRAFT/
/AT/
/AT/
/AT/
@ BIOCRAFT
@

1%
1%
1%
1%
1%
2.5%

N80400 001
APR 06, 1987
N80400 002
APR 06, 1987
N80400 003
APR 06, 1987
N80400 004

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

/AT/ /NASKA/ /2.5%/
/AT/ /PHARMADERM/ /1%/
@ PHARMADERM 1%
/N89662/001/
/MAR/16/1988/
/N88845/001/
/FEB/27/1986/
N88845 001
FEB 27, 1986

LOTION; TOPICAL

ACTICORT

/AT/ /NASKA/ /0.5%/
/AT/ /PHARMADERM/ /1%/
@ PHARMADERM 1%
/N86535/001/
/N86535/001/
/FEB/27/1986/
N86535 001
FEB 27, 1986

OINTMENT; TOPICAL

HYDROCORTISONE

AT FOUGERA 2.5%
/AT/ /PHARMADERM/ /1%/
@ PHARMADERM 1%
/N81203/001
MAY 28, 1993
/N88842/001/
/FEB/09/1987/
N88842 001
FEB 09, 1987

> DLT >
> DLT >
> ADD >
> ADD >

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

/AT/ /NASKA/ /1% EQ 3.5MG BASE/ML;
/AT/ /PHARMADERM/ /10,000 UNITS/ML;
@ PHARMADERM 1%; EQ 3.5MG BASE/ML;
10,000 UNITS/ML
/N62617/001
SEP 18, 1985
N62617 001
SEP 18, 1985

SUSPENSION/DROPS; OPHTHALMIC

/AT/ /NASKA/ /1% EQ 3.5MG BASE/ML;
/AT/ /PHARMADERM/ /10,000 UNITS/ML;
@ PHARMADERM 1%; EQ 3.5MG BASE/ML;
10,000 UNITS/ML
/N62623/001
SEP 24, 1985
N62623 001
SEP 24, 1985

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

/BP/ /BEL/MAR/ /25MG/ML/
/BP/ /BEL/MAR/ /50MG/ML/
@ BEL MAR 25MG/ML
@ 50MG/ML
/N83739/001/
/N83739/002/
N83739 001
N83739 002

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL

PRAMOXINE

/BP/ /FERNDALE/ /0.5%:1%/
/BP/ /FERNDALE/ /0.5%:1%/
@ FERNDALE 0.5%:1%
/N83213/002/
N83213 002

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

HYDROXOCOB

/AP/ /BEL/MAR/ /1MG/ML/
@ BEL MAR 1MG/ML
/N84629/001/
N84629 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

HYDROXYZINE HCL

AP FUJISAWA 25MG/ML
AP FUJISAWA 50MG/ML
/BP/ /JYPHOMED/ /25MG/ML/
/BP/ /JYPHOMED/ /50MG/ML/
N88184 001
MAR 31, 1983
N88185 001
MAR 31, 1983
/N88184/001/
/MAR/31/1983/
/N88185/001/
/MAR/31/1983/
N88184 001
MAR 31, 1983
N88185 001
MAR 31, 1983

SYRUP; ORAL

HYDROXYZINE HCL

AA BARRE 10MG/5ML
/AA/ /NASKA/ /10MG/5ML/
N88785 001
FEB 03, 1988
/N88785/001/
/FEB/03/1988/

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL

HYDROXYZINE HCL

/AB/ /CHELSEA/

/10MG/ /N86827/001/
 /25MG/ /N86829/001/
 /50MG/ /N86836/001/
 10MG N86827 001
 25MG N86829 001
 50MG N86836 001

TABLET; ORAL

LOZOL

RHONE POULENC RORER 1.25MG

N18538 002
 APR 29, 1993

IBUPROFEN

TABLET; ORAL

IBUPROFEN

AB NORTON HN

400MG /N71145/001/
 600MG /N71146/001/
 800MG /N71769/001/
 MAY 08, 1987

N71145 001
 SEP 23, 1986
 N71146 001
 SEP 23, 1986
 N71769 001
 MAY 08, 1987

IOHEXOL

INJECTABLE; INJECTION

/OMNIPAQUE/160/
 /STERLING/

> DLT > /36.8%/
 > DLT >
 > DLT >

/N17313/001/
 N17313 001

/N18956/001/
 /DEC/26/1985/

IBUPROFEN

/AB/ /PAR/

3 PAR

/300MG/ /N70328/001/
 300MG /N70328/001/
 AUG 06, 1985

N70328 001
 AUG 06, 1985

ILEN/

/AB/ /LUCHEM/

/AB/

/400MG/ /N71145/001/
 /600MG/ /N71146/001/
 /800MG/ /N71769/001/
 /N71145/001/
 /SEP/23/1986/
 /N71146/001/
 /SEP/23/1986/
 /N71769/001/
 /MAY/08/1987/

N71145 001
 SEP 23, 1986
 N71146 001
 SEP 23, 1986
 N71769 001
 MAY 08, 1987

/51.8%/
 /64.7%/
 /N18956/002/
 /DEC/26/1985/
 /N18956/003/
 /DEC/26/1985/

SOLUTION; INJECTION, ORAL

/OMNIPAQUE/240/
 /STERLING/

> DLT >
 > DLT > /51.8%/
 > DLT >
 > DLT > /64.7%/
 > DLT >

SOLUTION; INJECTION, ORAL, RECTAL

OMNIPAQUE 180
 + STERLING

OMNIPAQUE 240
 + STERLING

OMNIPAQUE 300
 + STERLING

38.8%
 51.8%
 64.7%

N18956 001
 DEC 26, 1985

N18956 002
 DEC 26, 1985

N18956 003
 DEC 26, 1985

IDOXURIDINE

/OINTMENT/OPHTHALMIC/

/STOXIL/

3 SMITHKLINE BEECHAM

/0.5%/
 0.5% SMITHKLINE BEECHAM

/N15868/001/
 N15868 001

N15868 001
 N15868 001

SOLUTION/DROPS; OPHTHALMIC

/STOXIL/

3 SMITHKLINE BEECHAM

/0.1%/
 0.1% SMITHKLINE BEECHAM

/N13934/001/
 N13934 001

IOTROLAN

/INJECTABLE/INTRATHECAL/
 /SNOVIST/
 /BERLEX/

/Eq/1.90MG/100INE/ML/
 /Eq/2.40MG/100INE/ML/

/N19560/001/
 /DEC/07/1989/
 /N19560/002/
 /DEC/07/1989/

ISOTROLAN

/INJECTABLE; INTRATHETICAL/
/OSMOVIST/
@ BERLEX

EQ 190MG IODINE/ML
EQ 240MG IODINE/ML

N19580 001
DEC 07, 1989
N19580 002
DEC 07, 1989

/TABLET; ORAL/
/PARBID/
/SMITHKLINE BEECHAM/
@ SMITHKLINE BEECHAM

/EQ; 5MG BASE/
EQ 5MG BASE

/N10744/001/
N10744 001

IRON DEXTRAN

INJECTABLE; INJECTION
INFED

BP + SCHEIN PHARM
/IRON/DEXTRAN/
/BP/ /STERIS/
/EQ; 50MG IRON/ML/
/N17441/001/

N17441 001

TABLET; RECTAL, SUBLINGUAL
ISUPREL
/STERLING/
@ STERLING

/15MG/
15MG

/N06328/002/
N06328 002

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
/AN/ /ASTRA/

@ ASTRA

@

/AN/ /PARKE/DAVIS/
@ PARKE DAVIS
@

/0.125%/
/0.062%/
0.062%
0.125%

/1%/
/0.5%/
0.5%
1%

/N87937/001/
/NOV/15, 1982/
/N87937/001/
/NOV/15, 1982/
/N87937 001
NOV 15, 1982
N87938 001
NOV 15, 1982
/N85889/001/
/N85997/001/
N85997 001
N85889 001

TABLET; ORAL
SORBITRATE
/AD/ /ICI/
/AD/ /ICI/
/AD/ /ICI/
AB ZENECA
AB
AB

/40MG/
/30MG/
/40MG/
20MG
30MG
40MG

/N86405/002/
/AUG/21, 1990/
/N86405/001/
/AUG/21, 1990/
/N86405/001/
/AUG/21, 1990/
/N86405 002
AUG 21, 1990
N88124 001
AUG 21, 1990
N88125 001
AUG 21, 1990

ISOFLURANE

LIQUID; INHALATION
FORANE
+ ANAQUEST
ISOFLURANE
AN ABBOTT

99.9%

99.9%

N17624 001

N74097 001
JAN 25, 1993

TABLET; ORAL
ISMO
/DLT > /AD/ /ICI/ /MFE/TH/
> DLT >
> ADD >
> ADD >

/40MG/
20MG
20MG
10MG

/N19091/001/
/DEC/30, 1991/
N19091 001
DEC 30, 1991
N20215 001
JUN 30, 1993
N20215 002
JUN 30, 1993

ISONIAZID

TABLET; ORAL
/STANDARD/
/EVERYLIFE/
@ EVERYLIFE

/300MG/
300MG

/N80126/002/
N80126 002

KANAMYCIN SULFATE

INJECTABLE; INJECTION

/AB/ /KLEBCELL/
/SMITHKLINE/BEECHAM/
/AB/ /EQ 15MG BASE/2ML/
/AB/ /EQ 500MG BASE/2ML/
/AB/ /EQ 1GM BASE/3ML/
3 SMITHKLINE BEECHAM
3 EQ 75MG BASE/2ML
3 EQ 500MG BASE/2ML
3 EQ 1GM BASE/3ML

/N62170/001/
/N62170/002/
/N62170/003/
N62170 001
N62170 002
N62170 003

SOLUTION; ORAL, RECTAL

AA CEPHULAC
MERRELL DOM
AA ENULOSE
BARRE

10GM/15ML
10GM/15ML

N17657 001
N71548 001
AUG 15, 1988

AA GENERLAC
PHARM BASICS

10GM/15ML

N71842 001
SEP 27, 1988

KETOPROFEN

CAPSULE; ORAL

AA KETOPROFEN
LEDERLE
AB 25MG
AB 50MG
AB 75MG

N74014 001
JAN 29, 1993
N74014 002
JAN 29, 1993
N74014 003
JAN 29, 1993

10GM/15ML
10GM/15ML
10GM/15ML
10GM/15ML
10GM/15ML

N73504 001
MAY 28, 1993
N17906 001
/N73374/001/
/MAR/22/1989/
N72374 001
MAR 22, 1989

LACTULOSE

SOLUTION; ORAL

/AB/ /CEPHULAC/
/MERRELL/DOM/
/AB/ /ENULOSE/
/BARRE/
AA EVALOSE
COPLEY

/N17657/001/
/N71548/001/
/AUG/15/1988/

EQ 10MG BASE
EQ 15MG BASE
EQ 5MG BASE

N71962 001
NOV 19, 1987
N71104 001
MAR 04, 1987
N72733 001
FEB 22, 1993
N72734 001
FEB 22, 1993
N72735 001
FEB 22, 1993
N72736 001
FEB 22, 1993

AA HEPTALAC
COPLEY

N73497 001
MAY 28, 1993

EQ 10MG BASE

/AB/ /GENERLAC/
/PHARM/BASICS/
/AB/ /LACTULOSE/
/SOLVAY/
AA LAXULOSE
TECHNILAB

/N71842/001/
/SEP/27/1988/
/N17906/001/

EQ 10MG BASE
EQ 15MG BASE
EQ 25MG BASE

N19010 001
APR 09, 1985
/N19010/001/
/APR/09/1985/
N20263 001
APR 16, 1993

SOLUTION; ORAL, RECTAL

AA ACILLAC
TECHNILAB

N73685 001
MAY 28, 1993

10GM/15ML
10GM/15ML
10GM/15ML
10GM/15ML
10GM/15ML

N19010 001
APR 09, 1985
/N19010/001/
/APR/09/1985/
N20263 001
APR 16, 1993

INJECTABLE; INJECTION

LUPRON
+ TAP

1MG/0.2ML

N19010 001
APR 09, 1985
/N19010/001/
/APR/09/1985/
N20263 001
APR 16, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

LUPRON DEPOT

+ TAP

3.75MG/VIAL

N20011 001
OCT 22, 1990

7.5MG/VIAL

N19732 001
JAN 26, 1989

/3.75MG/VIAL/

/N20011/001/

/7.5MG/VIAL/

/OCT 22, 1990/

LUPRON DEPOT-PED

+ TAP

3.75MG/VIAL&7.5MG/VIAL

N20263 003
APR 16, 1993

7.5MG/VIAL&7.5MG/VIAL

N20263 004
APR 16, 1993

7.5MG/VIAL

N20263 002
APR 16, 1993

> ADD >
> ADD >
> ADD >
> ADD >
> ADD >

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

ORLAAM

BIOMETRIC RES

10MG/ML

N20315 001
JUL 09, 1993

JELLY; TOPICAL

LIDOCAINE HCL

AT

COPLEY

2%

N81318 001
APR 29, 1993

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

/INJECTABLE; INJECTION/
/RAVOCALINE/AND/NOXOCALINE/
/COOK/WHITE/
@ STERLING WINTHROP

/N08592/001/
N08592 007
0.05MG/ML; 2%; 5.0%

TABLET; ORAL
THYROLAR-0.25
FOREST LABS
/RHONE/POULENC/ROREER//0.0125MG; 0.0031MG/
THYROLAR-0.5
FOREST LABS
/RHONE/POULENC/ROREER//0.025MG; 0.00625MG/
THYROLAR-1
FOREST LABS
/RHONE/POULENC/ROREER//0.05MG; 0.0125MG/
THYROLAR-2
FOREST LABS
/RHONE/POULENC/ROREER//0.1MG; 0.025MG/
THYROLAR-3
FOREST LABS
/RHONE/POULENC/ROREER//0.15MG; 0.0375MG/
THYROLAR-5
FOREST LABS
/RHONE/POULENC/ROREER//0.25MG; 0.0625MG/

N16807 001
/N16807/001/
N16807 005
/N16807/005/
N16807 004
/N16807/004/
N16807 002
/N16807/002/
N16807 003
/N16807/003/
N16807 006
/N16807/006/

> DLT >
> DLT >
> DLT >
> ADD >

LIDOCAINE

/SUPPOSITORY; RECTAL/
/XYLOCAINE/
/ASTRA/
@ ASTRA

/100MG/
100MG

/N13077/001/
N13077 001

/N86761/001/
/N86761/001/
N80710 001
N80760 001
/N86761/001/
/N86761/001/
N80404 002
N80404 003
N80390 001
N80390 002
/N86761/001/
/N86761/001/
/N86761/001/
/N86761/001/
N86761 001
N86761 002

1%
2%
1%
2%
1%
2%
1%
2%
1%
2%
1%
2%
1%
2%
1%
2%

INJECTABLE; INJECTION

LIDOCAINE HCL

/AP/

/AP/

@ BEL MAR

@

/BRISTOL/

/AP/

/AP/

AP

AP

@

@

/LYPHOMED/

/AP/

/AP/

/AP/

/AP/

@

@

@ LYPHOMED

LISINAPRIL

TABLET; ORAL

ZESTRIL
/AB/ /IMPERIAL/CHEM/

/5MG/

/N19777/001/
/MAY 19, 1988/

/10MG/

/N19777/002/
/MAY 19, 1988/

/20MG/

/N19777/003/
/MAY 19, 1988/

/40MG/

/N19777/004/
/MAY 19, 1988/

/2.5MG/

/N19777/005/
/MAY 19, 1988/

AB ZENECA

5MG

N19777 001
MAY 19, 1988

AB

10MG

N19777 002
MAY 19, 1988

AB

20MG

N19777 003
MAY 19, 1988

AB +

40MG

N19777 004
MAY 19, 1988

2.5MG

N19777 005
APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL

ESKALITH
/AB//+//SMITHKLINE/BEECHAM/

/300MG/

/N17971/001/
/N17971 001

300MG

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE
PENNEX PHARMS

> ADD > AA

> ADD >

> DLT > /AA/

> DLT >

EQ 300MG CARBONATE/5ML

N70755 001

MAY 21, 1986

/EQ 300MG CARBONATE/5ML/

/N17755/001/
/MAY 21, 1986/

LORATADINE

TABLET; ORAL

CLARITIN
+ SCHERING

10MG

N19658 001

APR 12, 1993

MAFENIDE ACETATE

CREAM; TOPICAL

SULFAMYLOL
+ HICKAM

/SIFERLINS/

EQ 85MG BASE/GM

/EQ 85MG BASE/GM/

N16763 001

/N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION

MANGANESE SULFATE

FUJISAWA

/LYPHOMED/

EQ 0.1MG MANGANESE/ML

/EQ 0.1MG MANGANESE/ML/

N19228 001

MAY 05, 1987

/N19228/001/
/MAY 05, 1987/

MANNITOL

INJECTABLE; INJECTION

MANNITOL 10% IN PLASTIC CONTAINER

> ADD > AP

> ADD >

MCGAM

10GM/100ML

N20006 002

JUL 26, 1993

> ADD > AP

> ADD >

MANNITOL 15% IN PLASTIC CONTAINER

MCGAM

15GM/100ML

N20006 003

JUL 26, 1993

> ADD > AP

> ADD >

MANNITOL 20% IN PLASTIC CONTAINER

MCGAM

20GM/100ML

N20006 004

JUL 26, 1993

> ADD > AP

> ADD >

MANNITOL 5% IN PLASTIC CONTAINER

MCGAM

5GM/100ML

N20006 001

JUL 26, 1993

MASOPROCOL

CREAM; TOPICAL

ACTINEX
+ BLOCK DRUG

/SICHEMEX/

10%

/14%/

N19940 001

SEP 04, 1992

/N19940/001/
/SEP 04, 1992/

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION

/SYNKAVITE/
/ROCHE/

5MG/ML/
10MG/ML/
37.5MG/ML/

N03718/004/
N03718/006/
N03718/008/

MENADIOL SODIUM DIPHOSPHATE

INJECTABLE; INJECTION
/SYNKAVITE/

3
3
3

5MG/ML
10MG/ML
37.5MG/ML

N03718 004
N03718 006
N03718 008

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21

/AB/ /SCHIAPPARELLI/SEARLE/0.05MG;1MG/

/N71539/001/
/APR 12, 1988/

TABLET; ORAL
/SYNKAVITE/
/ROCHE/
3

/5MG/
5MG

/N03718/010/
N03718 010

TABLET; ORAL-28

NORETHIN 1/50M-28

AB ROBERTS

0.05MG;1MG

N71540 001
APR 12, 1988
/N71540/001/
/APR 12, 1988/

/AB/ /SCHIAPPARELLI/SEARLE/0.05MG;1MG/

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

>_ADD > AP
>_ADD >

ASTRA

10MG/ML

N81002 001
JUL 30, 1993

MESTRANOL; NORETHYNODREL

TABLET; ORAL
/ENOVID/
/SEARLE/

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE
/LEE/LABS/

/400MG/
400MG

3 LEE LABS

/N89538/001/
/NOV 25, 1987/
N89538 001
NOV 25, 1987

METARAMINOL BITARTRATE

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

AP FUJISAWA

AP /AP/
/BE/ /LPHHMD/

EQ 10MG BASE/ML
EQ 10MG BASE/ML
EQ 10MG BASE/ML
EQ 10MG BASE/ML

N80431 001
N80722 001
/N80431/001/
/N80722/001/

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL

PENTASA

+ MARION MERRELL DOW 250MG

N20049 001
MAY 10, 1993

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADONE

AA MALLINCKRODT

5MG

MESTRANOL; NORETHINDRONE

TABLET; ORAL-28

/NOBINTYL/

/SYNTEX/

3 SYNTEX

/0.1MG;2MG/
0.1MG;2MG

N40050 001
APR 15, 1993
N40050 002
APR 15, 1993

TABLET; ORAL-21

NORETHIN 1/50M-21

AB ROBERTS

0.05MG;1MG

/N17058/001/
N13625 004
N71539 001
APR 12, 1988

TABLET, DISPERSIBLE; ORAL

METHADONE HCL

LILLY

AA METHADONE

40MG

AA MALLINCKRODT

40MG

N17058 001
N76184 001
APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL
/METHAMPHETAMINE/
/LEMON/
@ LEMON

/10MG/
10MG

/N83889/001/
N83889 001

/AA/
/PIONEER/PHARMS/
/500MG/
/150MG/
500MG
750MG

/N86731/001/
DEC 13, 1985
/N89082/001/
DEC 13, 1985
/N87453/001/
/N87454/001/
N87453 001
N87454 001

METHAMPHETAMINE HCL

/LEMON/
@ LEMON
/REXAR/
REXAR

/5MG/
5MG
/10MG/
10MG

/N86359/001/
N86359 001
/N84931/002/
N84931 002

METHANTHIELINE BROMIDE

TABLET; ORAL
BANTHINE
ROBERTS

/SCHAPPARELLI/SEARLE/50MG/
50MG

/N07390/001/
N07390 001

> ADD >

> DLT >

METHAZOLAMIDE

TABLET; ORAL
METHAZOLAMIDE
COPELY

/25MG/
50MG

N40001 001
JUN 30, 1993
N40001 002
JUN 30, 1993
N40036 001
JUN 30, 1993
N40036 002
JUN 30, 1993

NEPTAZANE
LEDERLE

/25MG/
50MG

N11721 002
NOV 25, 1991
N11721 001

AB +

METHOCARBAMOL

TABLET; ORAL
/DELAXIN/
/FERNDALE/
@ FERNDALE

/500MG/
500MG

/N85454/001/
N85454 001

METHOCARBAMOL
NYLOS TRADING

/750MG/
750MG

N85033 001

METHOCARBAMOL

TABLET; ORAL

METHOCARBAMOL
/PIONEER/PHARMS/
/500MG/
/750MG/
500MG
750MG

@ PIONEER PHARMS

@

> DLT > /AA/
> DLT > /AA/
> ADD > /AA/
> ADD > /AA/
/TALITICAPPS/
/UPSHER/SMITH/
@ UPSHER SMITH
@

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM
/AKORN/
/LYPHOMED/
@ LYPHOMED
AP NORBROOK

/EQ 25MG BASE/ML/
/EQ 25MG BASE/ML/
EQ 25MG BASE/ML
EQ 25MG BASE/ML

/N86648/001/
MAY 09, 1986
/N89263/001/
JUN 13, 1986
/N88648/001/
MAY 09, 1986

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL
/LYPHOMED/
@ LYPHOMED

/50MG/ML/
50MG/ML

/N70652/001/
JUN 03, 1986
N70652 001
JUN 03, 1986

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE
/CHELSEA/
B* CHELSEA

/4MG/
4MG

/N86161/001/
FEB 09, 1982
N86161 001
FEB 09, 1982

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION

/BP/ /M-PREDROL/
/BP/ /BEL/MAR/

/40MG/ML/
/80MG/ML/
40MG/ML
80MG/ML

/N86666/001/
/N87135/001/
N86666 001
N87135 001

METHYPRYLON

/TABLET; ORAL/
/NOLUDAR/
/ROCHE/
@ ROCHE

/200MG/
200MG

/N89668/004/
N09660 004

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

/BP/ /METHYLPREDNISOLONE SODIUM SUCCINATE/
/L-PHONED/

/EQ 40MG BASE/VIAL/
/EQ 125MG BASE/VIAL/
/EQ 500MG BASE/VIAL/
/EQ 1GM BASE/VIAL/

/N89143/001/
/MAR/28/1986/
/N89144/001/
/MAR/28/1986/
/N89187/001/
/MAR/28/1986/
/N89189/001/
/MAR/28/1986/
N89143 001
MAR 28, 1986
N89144 001
MAR 28, 1986
N89187 001
MAR 28, 1986
N89189 001
MAR 28, 1986

@ LYPHONED
EQ 40MG BASE/VIAL
@
EQ 125MG BASE/VIAL
@
EQ 500MG BASE/VIAL
@
EQ 1GM BASE/VIAL

SOLUTION; ORAL

METOCLOPRAMIDE HCL

AA LEMMON

EQ 5MG BASE/5ML

N71315 001
JUN 30, 1993
N71402 001
JUN 25, 1993

AA LIQUIPHARM

EQ 5MG BASE/5ML

METHYLTESTOSTERONE

CAPSULE; ORAL

/BP/ /METHYLTESTOSTERONE/
/HEATHER/

/10MG/
10MG

/N84967/001/
N84967 001

TESTRED

/BP/ /ICN/
BP + ICN

/10MG/
10MG

/N83976/001/
N83976 001

METHYPRYLON

/CAPSULE; ORAL/
/NOLUDAR/
/ROCHE/
@ ROCHE

/300MG/
300MG

/250MG/
250MG

/500MG/
500MG

/N70859/001/
/MAR/19/1985/
/N70731/001/
/JUN/88/1987/

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

/BP/ /AKORN/

/EQ 10MG BASE/2ML/

/N70892/001/
/AUG/26/1988/
/N70893/001/
/JAN/24/1986/
N70293 001
JAN 24, 1986
N70892 001
AUG 26, 1988

/BP/ /FUJISAMA/

/EQ 10MG BASE/2ML/

@ FUJISAMA

EQ 10MG BASE/2ML

@ NORBROOK

EQ 10MG BASE/2ML

TABLET; ORAL

METOCLOPRAMIDE HCL

AB BIOCRAFT

EQ 5MG BASE

N72801 001
JUN 15, 1993
N71536 001

AB MUTUAL PHARM

EQ 10MG BASE

APR 28, 1993
/N70344/001/
/MAR/25/1986/
N70342 001
MAR 25, 1986

/BP/ /PAR/

/EQ 10MG BASE/

@ PAR

EQ 10MG BASE

METRONIDAZOLE

TABLET; ORAL

/BP/ /SANTO/
/SAVAGE/

/BP/ /SANTO/
/SAVAGE/

/N89668/008/
N09660 008

METRONIDAZOLE

TABLET; ORAL
/SANTAL/
@ SAVAGE
250MG
N70029 001
MAR 19, 1985
500MG
N70731 001
JUN 08, 1987
INJECTABLE; INJECTION
NOVANTRONE
+ IMMUNEX
/LEPHERIE/
EQ 2MG BASE/ML
/EQ/2MG/BASE/ML/
N19297 001
DEC 23, 1987
/N19297/001/
/DEC/23,1987/

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION
MEZLIN
MILES
EQ 1GM BASE/VIAL
N62372 005
JAN 13, 1983

MICONAZOLE NITRATE

/CREAM; VAGINAL/
/MONISTAT/
/JOHNSON/RW/
/2/
/N17739/001/
OCT 17, 1988

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT DUAL-PAK
+ JOHNSON RW
2%:200MG
N18888 002

/LOTION; TOPICAL/
/MONISTAT-DERM/
/JOHNSON/RW/
@ JOHNSON RW
/2/
2%
/N17739/001/
N17739 001

/SUPPOSITORY; VAGINAL/
/MONISTAT/
/JOHNSON/RW/
/100MG/
/N18520/001/
/MAR/15,1982/

MILRINONE LACTATE

INJECTABLE; INJECTION
MILRINONE LACTATE
+ STERLING
/2/
EQ 1MG BASE/ML
/EQ/1MG/BASE/ML/
N19436 001
DEC 31, 1987
/N19436/001/
/DEC/31,1987/

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/PUPONY/
/250MG/
/250MG/
/300MG/
200MG
250MG
300MG
ROBERTS
N19753 001
JUN 19, 1990
N19753 002
JUN 19, 1990
N19753 003
JUN 19, 1990

NABILONE

/CAPSULE; ORAL/
/CESAMEY/
/LILLY/
@ LILLY
/1MG/
1MG
/N18677/001/
/DEC/26,1985/
N18677 001
DEC 26, 1985

NAFILLIN SODIUM

/POWDER FOR RECONSTITUTION; ORAL/
/UNIPEN/
/MYETH AYERST/
@ MYETH AYERST
/EQ/250MG/BASE/PHL/
EQ 250MG BASE/5ML
/N50199/001/
N50199 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HYDROCHLORIDE
ABBOTT
1.5MG/ML
N20200 001
MAR 12, 1993

NALOXONE HYDROCHLORIDE

INJECTABLE; INJECTION

NALOXONE HCL

/AB/ /L-PHYOMED/

/0.04MG/ML/

/N71083/001/
/NOV/17, 1986/
N70661 001

0.02MG/ML

NOV 17, 1986

3 LYPHOMED

/0.4MG/ML/

/N71083/001/
/JUL/28, 1988/

/AB/ /DUPONT/

/0.4MG/ML/

/N71084/001/

/AB/

/1MG/ML/

/N71084/001/

/AB/

/1MG/ML/

/N71311/001/

/AB/

/1MG/ML/

/N71311/001/

3 DUPONT

0.4MG/ML

N71083 001

3

1MG/ML

JUL 28, 1988

3

1MG/ML

JUL 28, 1988

JUL 28, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

/AB/ /L-PHYOMED/

/100MG/ML/

/N88290/001/
/OCT/03, 1983/

/AB/

/100MG/ML/

/N88317/001/
/OCT/14, 1983/

3 LYPHOMED

100MG/ML

N88290 001

3

200MG/ML

OCT 03, 1983

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

> DLI >/AB/ /EON/LABS/

> ADD >

/EQ 350MG BASE/

EQ 350MG BASE

/N61586/001/
N61586 001

NIACIN

/CAPSULE; ORAL/

/MALLACE/

3 WALLACE/

/500MG/

500MG

/N11073/003/

N11073 003

NIACIN

TABLET; ORAL

NIACIN

/AB/ /ZENITH/

3 ZENITH

/500MG/

500MG

/N83180/001/

N83180 001

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

/FLEMINGTON

10MG

N72781 001

JUL 30, 1993

> ADD > AB

> ADD >

TABLET, EXTENDED RELEASE; ORAL

ADALAT CC

BC MILES

30MG

N20198 001

APR 21, 1993

N20198 002

APR 21, 1993

N20198 003

APR 21, 1993

BC + PROCARDIA XL

BC + PFIZER

30MG

N19684 001

SEP 06, 1989

N19684 002

SEP 06, 1989

N19684 003

SEP 06, 1989

/N19684/001/
/SEP/06, 1989/

/N19684/002/
/SEP/06, 1989/

/N19684/003/
/SEP/06, 1989/

/N19684/001/
/SEP/06, 1989/

/N19684/002/
/SEP/06, 1989/

/N19684/003/
/SEP/06, 1989/

NITROFURANTOIN

TABLET; ORAL

NITROFURANTOIN

/AB/ /ZENITH/

3 ZENITH

/50MG/

50MG

/N80078/002/

N80078 002

SEP 06, 1989

N80078 001

/N61586/001/
N61586 001

/N11073/003/
N11073 003

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 7 / JAN '93 - JUL '93

39

NITROFURANTOIN, MACROCRYSTALLINE

AB CAPSULE; ORAL
NITROFURANTOIN
 ZENITH

AB 50MG N73671 001
 JAN 28, 1993
 AB 100MG N73652 001
 JAN 28, 1993

POWDER; ORAL
NYSTATIN
 BARSTADIN 100/
 BARLAN

AA /AA/ /100Z/
 @ BARLAN 100Z
 APR 27, 1988
 N62489 001
 N62489 001

NITROGLYCERIN

INJECTABLE; INJECTION
 NITRO-BID
 MARION/MERRELL/DOW /10MG/ML/
 @ MARION MERRELL DOW 10MG/ML

> DLT >
 > DLT >
 > ADD >
 > ADD >

AA /AA/ /N71159/001/
 /FEB/28, 1990/
 N71159 001
 FEB 28, 1990

SUSPENSION; ORAL

AA /AA/ MYCOSTATIN
 APOTHECON 100,000 UNITS/ML
 /PERSTOL/NYERS/S&J/BB/ /100,000 UNITS/ML/
 NYSTATIN
 AA BARRE 100,000 UNITS/ML
 /AA/ /NAASKA/ /100,000 UNITS/ML/
 /AA/ /PHARMADERM/ /100,000 UNITS/ML/
 @ PHARMADERM 100,000 UNITS/ML

N61533 001
 /N61533/001/
 N62571 001
 OCT 29, 1985
 /N62571/001/
 /OCT/29, 1985/
 /N62571/001/
 /JUL/06, 1984/
 N62518 001
 JUL 06, 1984

NORTRIPTYLINE HYDROCHLORIDE

AB CAPSULE; ORAL
NORTRIPTYLINE HCL
 MYLAN

> ADD > AB EQ 10MG BASE N74234 001
 > ADD > AB EQ 25MG BASE N74234 002
 > ADD > AB EQ 50MG BASE N74234 003
 > ADD > AB EQ 75MG BASE N74234 004
 > ADD >

JUL 26, 1993
 JUL 26, 1993
 JUL 26, 1993
 JUL 26, 1993

NYSTATIN; TRIAMCINOLONE ACETONIDE

AI CREAM; TOPICAL
NYSTATIN AND TRIAMCINOLONE ACETONIDE
 /AI/ /NAASKA/ /100,000 UNITS/GM;0.1Z/
 /AI/ /PHARMADERM/ /100,000 UNITS/GM;0.1Z/
 @ PHARMADERM 100,000 UNITS/GM;0.1Z

N63010 001
 DEC 20, 1988
 /N63010/001/
 /DEC/20, 1988/
 /N62596/001/
 /OCT/08, 1985/
 N62596 001
 OCT 08, 1985

NYSTATIN

AI CREAM; TOPICAL
NYSTATIN
 BARRE

AI /AI/ /NAASKA/ 100,000 UNITS/GM
 AI TARO 100,000 UNITS/GM

N62949 001
 JUN 13, 1988
 /N62949/001/
 /JUN/13, 1988/
 N64022 001
 JAN 29, 1993

AI OINTMENT; TOPICAL

NYSTATIN AND TRIAMCINOLONE ACETONIDE
 AI TARO 100,000 UNITS/GM;0.1Z

N63305 001
 MAR 29, 1993

OINTMENT; TOPICAL

AI NYSTATIN
 BARRE 100,000 UNITS/GM
 /AI/ /NAASKA/ /100,000 UNITS/GM/

N62840 001
 NOV 13, 1987
 /N62840/001/
 /NOV/13, 1987/

OCTREOTIDE ACETATE

INJECTABLE; INJECTION
SANDOSTATIN
/SANDOPZ/

/EQ/500UM/BASE/ML/

SANDOZ

EQ 0.05MG BASE/ML

/EQ/1000UM/BASE/ML/

EQ 0.1MG BASE/ML

EQ 0.2MG BASE/ML

/EQ/5000UM/BASE/ML/

EQ 0.5MG BASE/ML

EQ 1MG BASE/ML

/N19667/001/
/DEC/21, 1988/

OCT 21, 1988

/N19667/002/
/DEC/21, 1988/

OCT 21, 1988

N19667 004

JUN 12, 1991

/N19667/003/
/DEC/21, 1988/

OCT 21, 1988

N19667 005

JUN 12, 1991

N20036 003
MAY 06, 1993
N20036 004
MAY 06, 1993

/N12772/006/
/MAY/06, 1993/
N12772 005
N12772 006

PARAMETHASONE ACETATE

TABLET; ORAL

HALDRONE

/+//LILLY/

3 LILLY

3

/2MG/
/1MG/
1MG
2MG

PAROXETINE HYDROCHLORIDE

TABLET; ORAL

PAXIL

/+//SMITHKLINE/BEECHAM/

/+//

3 SMITHKLINE BEECHAM

3

/EQ/10MG/BASE/
/EQ/50MG/BASE/
EQ 10MG BASE
EQ 40MG BASE
EQ 50MG BASE

/N20031/001/
/DEC/29, 1992/
N20031 001
DEC 29, 1992
/N20031/005/
/DEC/29, 1992/
N20031 005
DEC 29, 1992

OPRENOLOL HYDROCHLORIDE

/CAPSULE; ORAL/
TRASICOR/
/+//CIBA/

/3.0MG/

/2.0MG/

/4.0MG/

/8.0MG/

3 CIBA

3

3

3

20MG

40MG

80MG

160MG

/300,000/UNITS/ML/
300,000 UNITS/ML
300,000 UNITS/ML
/300,000/UNITS/ML/

/N50141/003/
N50141 003
N50131 001
/N50141/003/

/200,000/UNITS/
200,000 UNITS

/N50128/001/
N50128 001

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

OCUFLOX

+ ALLERGAN

0.3%

N19921 001

JUL 30, 1993

/N18166/004/
/DEC/28, 1983/

DEC 28, 1983

/N18166/001/
/DEC/28, 1983/

DEC 28, 1983

/N18166/002/
/DEC/28, 1983/

DEC 28, 1983

/N18166/003/
/DEC/28, 1983/

DEC 28, 1983

N18166 001

DEC 28, 1983

N18166 002

DEC 28, 1983

N18166 003

DEC 28, 1983

N18166 004

DEC 28, 1983

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

/AA/ PENICILLIN /200,000 UNITS/5ML/ N60307/002/ N60307 002
 /AA/ BIOCRRAFT /200,000 UNITS/5ML/ N60307 002
 /AA/ BIOCRRAFT /200,000 UNITS/5ML/ N60307 002
 /AA/ PENTIDS '400' /200,000 UNITS/5ML/ N62149 001
 /AA/ PENTIDS '400' /200,000 UNITS/5ML/ N62149 001
 /AA/ PENTIDS '400' /400,000 UNITS/5ML/ N62149 002
 /AA/ PENTIDS '400' /400,000 UNITS/5ML/ N62149 002

TABLET; ORAL
PENICILLIN G POTASSIUM

/AB/ APOTHECON /250,000 UNITS/ N60392 003
 /AB/ APOTHECON /250,000 UNITS/ N60392 003
 /AB/ APOTHECON /200,000 UNITS/ N62155 001
 /AB/ APOTHECON /200,000 UNITS/ N62155 001
 /AB/ APOTHECON /250,000 UNITS/ N62155 002
 /AB/ APOTHECON /250,000 UNITS/ N62155 002
 /AB/ APOTHECON /400,000 UNITS/ N60392 004
 /AB/ APOTHECON /400,000 UNITS/ N60392 004
 /AB/ APOTHECON /400,000 UNITS/ N62155 003
 /AB/ APOTHECON /800,000 UNITS/ N60392 005
 /AB/ APOTHECON /800,000 UNITS/ N62155 004
 /AB/ APOTHECON /800,000 UNITS/ N62155 004

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

/AB/ DURACILLIN A.S. /300,000 UNITS/ML/ N60093 001
 /AB/ LILLY /300,000 UNITS/ML/ N60093 001
 /AB/ LILLY /300,000 UNITS/ML/ N60093 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

/AA/ PENTIDS '125' /EQ 125MG BASE/5ML/ N61206 001
 /AA/ PENTIDS '125' /EQ 125MG BASE/5ML/ N61206 001
 /AA/ PENTIDS '125' /EQ 125MG BASE/5ML/ N62153 001
 /AA/ APOTHECON /EQ 125MG BASE/5ML/ N62153 001
 /AA/ APOTHECON /EQ 125MG BASE/5ML/ N62153 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

/AA/ PENTIDS '250' /EQ 250MG BASE/5ML/ N61206 002
 /AA/ PENTIDS '250' /EQ 250MG BASE/5ML/ N61206 002
 /AA/ PENTIDS '250' /EQ 250MG BASE/5ML/ N62153 002
 /AA/ APOTHECON /EQ 250MG BASE/5ML/ N62153 002
 /AA/ APOTHECON /EQ 250MG BASE/5ML/ N62153 002

TABLET; ORAL

/AB/ PENTIDS '250' /EQ 250MG BASE/ N61164 001
 /AB/ PENTIDS '250' /EQ 250MG BASE/ N61164 001
 /AB/ PENTIDS '250' /EQ 250MG BASE/ N62156 002
 /AB/ PENTIDS '250' /EQ 250MG BASE/ N62156 002
 /AB/ APOTHECON /EQ 250MG BASE/ N61164 001
 /AB/ APOTHECON /EQ 250MG BASE/ N61164 001
 /AB/ APOTHECON /EQ 250MG BASE/ N62156 002
 /AB/ APOTHECON /EQ 250MG BASE/ N62156 002
 /AB/ APOTHECON /EQ 500MG BASE/ N61164 002
 /AB/ APOTHECON /EQ 500MG BASE/ N61164 002
 /AB/ APOTHECON /EQ 500MG BASE/ N62156 001
 /AB/ APOTHECON /EQ 500MG BASE/ N62156 001

PERMETHRIN

/LOTION; TOPICAL/
 /AT/ BURROUGHS WELLCOME /12/ N19435 001
 /AT/ BURROUGHS WELLCOME /12/ N19435 001
 /AT/ BURROUGHS WELLCOME /12/ N19435 001
 /AT/ BURROUGHS WELLCOME /12/ N19435 001

PERPHENAZINE

/TABLET; EXTENDED RELEASE; ORAL/
 /S/ SCHERING /8MG/ N11361 002
 /S/ SCHERING /8MG/ N11361 002
 /S/ SCHERING /8MG/ N11361 002
 /S/ SCHERING /8MG/ N11361 002

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL

> DLT > /STATOBEN/ /35MG/ N85507 001
 > DLT > /LEMON/ /35MG/ N85507 001
 > ADD > /LEMON/ /35MG/ N85507 001

TABLET; ORAL

/AB/ FERNDAL /35MG/ N83655 001
 /AB/ FERNDAL /35MG/ N83655 001
 /AB/ FERNDAL /35MG/ N83655 001
 /AB/ FERNDAL /35MG/ N83655 001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

/AA/ /MIRA/
/FOREST/PHARMS/
a FOREST PHARMS/35MG/
35MG/N83754/001/
N83754 001PHENDIMETRAZINE TARTRATE/AA/ /ANABOLICS/
a ANABOLICS
/AA/ /FERNDALE/
a FERNDALÉ/35MG/
35MG
/35MG/
35MG/N86020/001/
N86020 001
/N86020/001/
/SEP/15/1983/
N86834 001
SEP 15, 1983PHEENTERINE HYDROCHLORIDE

CAPSULE; ORAL

/AA/ /ADIPEX-P/
/LEMON/
/OBESTIN-50/
/FERNDALE/
a FERNDALÉ/30MG/
/30MG/
30MG/N86911/001/
/N87144/001/
N87144 001PHEENTERINE HCL/AA/ a LEMON
/ZENITH/
a ZENITH30MG
/30MG/
30MGN86911 001
/N86329/001/
N86329 001PHENYLBUTAZONE

CAPSULE; ORAL

/AB/ /PHENYLBUTAZONE/
/CHELSEA/
B* CHELSEA/100MG/
100MG/N87756/001/
/DEC/17/1982/
N87756 001
DEC 17, 1982PHYTONADIONE

INJECTABLE; INJECTION

AQUAPHYTON

/BP/ /MSD/
BP + MSD
/BP/+ /ROCHE/
BP ROCHE/10MG/ML/
10MG/ML
/10MG/ML/
10MG/ML/N12223/001/
N12223 001
/N11745/003/
N11745 003PINDOLOL

TABLET; ORAL

/AB/ /PINDOLOL/
GENEVA

/5MG

N73608 001
MAR 29, 1993

/10MG

N73609 001
MAR 29, 1993

/5MG

N74125 001
APR 28, 1993

/10MG

N74125 002
APR 28, 1993

/5MG

N73687 001
FEB 26, 1993

/10MG

N73687 002
FEB 26, 1993PIROXICAM

CAPSULE; ORAL

/AB/ /PIROXICAM/
MEPHA AG

/10MG

N74116 001
JUN 15, 1993

/20MG

N74118 001
JUN 15, 1993

/10MG

N73535 001
MAR 12, 1993

/20MG

N73536 001
MAR 12, 1993

/10MG

N73651 001
FEB 26, 1993

/20MG

N73651 002
FEB 26, 1993POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

/AB/ /K-LEASE/
/ADRIA/

/8MEG/

/N73398/001/
/JAN/28/1992/
/N73398/001/
/MAR/28/1990/

/10 MEG/

/8MEG

N73398 001
JAN 28, 1992

/10 MEG

N72427 001
MAR 28, 1990

POTASSIUM CHLORIDE

INJECTABLE; INJECTION
POTASSIUM CHLORIDE

AP FUJISAWA

2MEQ/ML
2MEQ/ML

N84290 001
N87787 001

AP /
AP /

2MEQ/ML /
2MEQ/ML /

APR 20, 1982
/N86221/001 /
/N80736/001 /
N80221 001

AP /
AP /

2MEQ/ML /
2MEQ/ML /

N80736 001
/N84290/001 /
/N87787/001 /
/APR/20/1982/

TABLET, EXTENDED RELEASE; ORAL

AB ALRA

8MEQ

N70998 001

KAON CL

/ADRIA/

SAVAGE

10MEQ /

6.7MEQ

KAON CL-10

/ADRIA/

SAVAGE

10MEQ /

10MEQ

POTASSIUM CITRATE

/POWDER/FOR RECONSTITUTION; ORAL /
POTASSIUM CITRATE /
/UNIV/TX /

10MEQ/PACKET /

10MEQ/PACKET /

10MEQ/PACKET

20MEQ/PACKET

20MEQ/PACKET

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

+ UNIV TX

UNIV TX

10MEQ

5MEQ

/N19071/001 /
/AUG/30/1985 /
N19071 002

AUG 31, 1992

N19071 001

AUG 30, 1985

PRAVASTATIN SODIUM

TABLET; ORAL

PRAVACHOL

/+//PARKE/DAVIS/

10MG /

10MG

/N19568/001 /
/OCT/31/1991 /
N19898 004

MAR 22, 1993

N19898 003

OCT 31, 1991

PRAZEPAM

TABLET; ORAL /

CENTRA /

/+//PARKE/DAVIS /

10MG /

10MG

/N17415/001 /
N17415 001

PREDNICARBATE

ointment; TOPICAL

/DERMATOP /

/HOECHST/ROUSSEL /

0.1%

0.1%

/N19568/001 /
/SEP/23/1991 /
N19568 001

SEP 23, 1991

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

/WEST/WARD /

5MG /

5MG

> DLT >

> ADD >

/N19647/002

/OCT/13/1988 /

/N19647/001 /

/OCT/13/1988 /

N19647 002

OCT 13, 1988

N19647 001

OCT 13, 1988

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

STERIS

EQ 0.23% PHOSPHATE;10%

MAY 27, 1993

N73630 001

AUG 26, 1988

AT

PREDNISONE

TABLET; ORAL

DELTAZONE

UP JOHN

AB /BX/

2.5MG / 2.5MG/

N09986 005 /N09986/005/

PREDNISONE

HEATHER/

AB /AB /AB /AB/

10MG / 10MG / 20MG / 50MG / 10MG

/N04441/001/ /N05543/001/ /N05946/001/ /N04341 001

3 HEATHER

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHACON

/ALCON/

BR /BR/

POLYMEDICA

BR /BR/

25MG/

50MG/

25MG

50MG

/N04901/001/ /N04902/001/ /N04901 001 /N04902 001

TABLET; ORAL

PROMETHAZINE HCL

/BOLAR/

a BOLAR/

/ZENITH/

a ZENITH

25MG/

25MG/

25MG

50MG

/N03204/001/ /N03204 001 /N03613/001/ /N03613 001

PROPOFOL

INJECTABLE; INJECTION

DIPRIVAN

/IC/

+

ZENECA

> DLT >

> DLT >

> ADD >

> ADD >

10MG/ML/

10MG/ML

/N19627/001/ /N19627/001/ /N19627 001 /N19627 001

PROPRANLOL HYDROCHLORIDE

/SUSPENSION; ORAL/

/MYETH/AYERST/

a MYETH AYERST

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

10MG/ML/

10MG/ML

/N19536/001/ /N19536/001/ /N19536 001 /N19536 001

TABLET; ORAL

PROPRANLOL HCL

/MYLAN/

a MYLAN

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

> DLT >

> DLT >

> ADD >

> ADD >

60MG/

60MG

/N72275/001/ /N72275/001/ /N72275 001 /N72275 001

PROPYLIDONE

/SUSPENSION; INTRATRACHEAL/

/GLAXO/

a GLAXO

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

3

60%/

60%

/N09309/001/ /N09309 002

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINAMIDE HCL

/LYPHOMED/

AB /AB/

100MG/ML / 500MG/ML/

/N04415/001/ /N04415/001/ /N04415 001 /N04415 001

NOV 17, 1986

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/AP/ /QUAD/
@ QUAD
10MG/ML

/N89306/001/
/MAY/30./1986/
N89306 001
MAY 30, 1986

> DLT >
> DLT >
> ADD >

INJECTABLE; INJECTION

/100MG/ML/
100MG/ML

/N80854/001/
N80854 001

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

/HISTAFED/
/LIFE/LABS/

> DLT >
> DLT >
> DLT >
> ADD >
> ADD >

/N88283/001/
/APR/26./1984/
N88283 001
APR 20, 1984

QUAZEPAM

TABLET; ORAL

DORAL
/+/BAKER/MORTON/

/15MG/
/1.5MG/

/N18708/001/
/DEC/21./1985/
/N18708/001/
/FEB/26./1987/
N18708 001
DEC 27, 1985
N18708 003
FEB 26, 1987

PYRANTEL PAMOATE

/SUSPENSION; ORAL/
/ANTHINTH/
/+/ROERIG/

/EQ/250MG/BASE/5ML/

/N1665/001/

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION

MESTINON

/AP/ /ICN/
AP ROCHE

/N09830/001/
N09830 001

TABLET, EXTENDED RELEASE; ORAL
/DURAGUIN/
/PARKE/DAVIS/
@ MARNER CHILCOTT

/330MG/
330MG

/N17917/001/
N17917 001

SYRUP; ORAL

MESTINON

/ICN/
ROCHE

/N15193/001/
N15193 001

QUINIDINE SULFATE

TABLET; ORAL

/AP/ /QUINIDINE SULFATE/
/PARKE/DAVIS/
@ MARNER CHILCOTT

/200MG/
200MG

/N83879/001/
N83879 001

TABLET; ORAL

MESTINON

/+/ICN/
+ ROCHE

/N09829/002/
N09829 002

TABLET, EXTENDED RELEASE; ORAL

MESTINON

/+/ICN/
+ ROCHE

/N11665/001/
N11665 001

RESERPINE

TABLET; ORAL

RESERPINE

/BP/ /LEMON

> DLT >
> DLT >
> DLT >
> DLT >
> ADD >
> ADD >
> ADD >
> ADD >

/0.1MG/
/0.25MG/
0.1MG
0.25MG

@ LEMON

@

/N69020/001
/MAR 07, 1985
/N69019/001
/MAR 07, 1985
/N89020/001
/MAR 07, 1985
/N89019/001
/MAR 07, 1985

SODIUM BICARBONATE
/INJECTABLE; INJECTION/
/SODIUM BICARBONATE/AN/PLASTIC CONTAINER/
/ABBOTT/
/1MEQ/ML/
/1MEQ/ML/
0.9MEQ/ML
1MEQ/ML

/N19443/001
/JUN 03, 1986
/N19443/002
/JUN 03, 1986
/N19443/001
/JUN 03, 1986
/N19443/002
/JUN 03, 1986

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

/N69019/001

/BP/ @ /SCHERING/
@ SCHERING

/0.1MG;4MG/
0.1MG;4MG

/N12265/003/
N12265 003

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION

RETODRINE HCL

/AP/ /QUAD/

/10MG/ML/
10MG/ML

/N70700/001/
/OCT 06, 1986/
N70700 001
OCT 06, 1986

SODIUM CHLORIDE
INJECTABLE; INJECTION

AP BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

/AP/ /LYPHOMED/

N88911 001
FEB 07, 1985
/N88911/001/
/FEB 07, 1985/
N19329 001
APR 22, 1987
/N19329/001/
/APR 22, 1987/

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER
@ FUJISAWA
/23.4MG/ML/
/23.4MG/ML/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION

CHROMITOPRE SODIUM

@ SQUIBB/

/2NC1/VIAL/
2NC1/VIAL

/N13993/002/
N13993 002

@ ARMOUR

@

/INJECTABLE; INJECTION/
/ACTHAR/SEL-SYNTHETIC/
/ARMOUR/
/40 UNITS/ML/
/80 UNITS/ML/
/40 UNITS/ML/
/80 UNITS/ML

/N17861/001/
/NOV 30, 1989/
N17861 001
N17861 002

SILVER SULFADIAZINE

/PRESSING; TOPICAL/

@ BIOPLASTY

@

1%

/N19608/001
/NOV 30, 1989
N19608 001

/STUBINAC/
/ENQUAY/

/N19608/001/
/NOV 30, 1989/

SOLUTION; ORAL

SODIUM IODIDE I 131

@ CIS/

CIS BIOINDUSTRIES

/50MCI/ML/
50MCI/ML

/N17315/001/
N17315 001

SOYBEAN OIL

INJECTABLE; INJECTION
NUTRELIPID 10%

AP MCGAM 10% N19531 001
MAY 28, 1993

AP MCGAM 20% N19531 002
MAY 28, 1993

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

/AB/ /CHELSEA/
B* CHELSEA
> DLT > /AB/ /UPSHER/SMITH/
> ADD > @ UPSHER SMITH

/25MG/
25MG
/25MG/
25MG

/N87078/001
N87078 001
/N87554/001
N87554 001

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON

MEDI PHYSICS 1MCI/ML

N20134 001
JUN 18, 1993

SULFADIAZINE

TABLET; ORAL

SULFADIAZINE

/ABBOTT/
@ ABBOTT

/300MG/
300MG

/N04125/005
N04125 005

SULFAMETHIZOLE

TABLET; ORAL

THIOSULFIL

/MYETH/AYERST/
@ WYETH AYERST

/250MG/
250MG

/N08565/001
N08565 001

SULFAMETHOXAZOLE

TABLET; ORAL

SANTANOL-D5/

/ROCHE/
@ ROCHE

/1GM/
1GM

/N12715/003
N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

TRIMETH/SULFA

AB BARRE 200MG/5ML; 40MG/5ML

N72289 001
MAY 23, 1988

AB 200MG/5ML; 40MG/5ML

N72398 001
MAY 23, 1988

/AB/ /NASKA/ /200MG/5ML; 40MG/5ML/

/N72289/001
/MAY/23/1988/

/AB/ /200MG/5ML; 40MG/5ML/

/N72398/001
/MAY/23/1988/

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

/AB/ /HEATHER/
@ HEATHER

/500MG/
500MG

/N80189/001
N80189 001

SULFISOXAZOLE ACETYL

/EMULSION; ORAL/
/LIPRO/SANTRISIN/
/ROCHE/
@ ROCHE

/EQ/1GM/BASE/5ML/
EQ 1GM BASE/5ML

/N09182/009
N09182 009

SULFISOXAZOLE DIOLAMINE

/OINTMENT; OPHTHALMIC/
/SANTRISIN/
/ROCHE/
@ ROCHE

/EQ/4%/BASE/
EQ 4% BASE

/N08414/002
N08414 002

SULINDAC

TABLET; ORAL

SULINDAC

AB MYLAN 150MG

N73038 001
JUN 22, 1993

AB 200MG

N73039 001
JUN 22, 1993

TIAMOXIFEN CITRATE

TABLET; ORAL

NOLVADEX
/SANTAR/

/EQ/10MG/BASE/

/N17978/001/

IAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
+ ZENECA

EQ 10MG BASE

N17970 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION

/A-N/S/TANNOUS/AGGREGATED/ALBUMIN/
/BS/ /NORTH/AM/CHEM/
@ NORTH AM CHEM

/N17916/001/
N17916 001

AN-MAA

/CIS/US/

SORIN

/TECHNETIUM/TC/99M/MAA/
/BS/ /MEDI/PHYSICS/
@ MEDI PHYSICS

/N17792/001/
N17792 001

/N17773/001/
N17773 001

TECHNETIUM TC-99M SODIUM Pertechnetate GENERATOR

SOLUTION; INJECTION, ORAL

/MINITEC/
/SQUIBB/
@ SQUIBB

/0.22-2.22Ci/GENERATOR/
0.22-2.22Ci/GENERATOR

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM

AB DANBURY PHARMA

15MG

N71446 001

AB

30MG

MAY 21, 1993

N71447 001

MAY 21, 1993

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

/AD/
/AG/
/AG/
/AG/

/BEL/MAR/
/45MG/ML/
/50MG/ML/
/100MG/ML/
25MG/ML
50MG/ML
100MG/ML

@ BEL MAR

@

@

/N80741 001

N80741 001

N80742 001

N80743 001

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

TESTOSTERONE PROPIONATE

/AD/
/AG/
/AG/
/AG/
/AG/

/45MG/ML/
/25MG/ML/
/50MG/ML/
/100MG/ML/
/100MG/ML/
25MG/ML
100MG/ML
25MG/ML
100MG/ML

+ STERIS

+

/N80188/001
N80188 001
N80188 003
N85490 001
N83595 003

TETRACYCLINE HYDROCHLORIDE

TABLET; ORAL

SUMYCIN
APOTHECON

AB

50MG
100MG
250MG
500MG
/50MG/
/100MG/
/250MG/
/500MG/

N61147 003
N61147 002
N61147 001
N61147 004
/N61147/001/
/N61147/002/
/N61147/001/
/N61147/001/
/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

THALLOUS CHLORIDE TL 201

/AB/
/SQUIBB/

/1MCI/ML/
1MCI/ML

@ SQUIBB

/N18548/001/
/DEC/30,1982/
N18548 001
DEC 30, 1982

THEOPHYLLINE

ELIXIR; ORAL

/THEOPHYLLINE-225/
/JOHNSON/RW/
@ JOHNSON RW

/112.5MG/15ML/
112.5MG/15ML

THEOPHYLLINE

BARRE

80MG/15ML

N89223 001

MAY 27, 1988

/N89223/001/
/MAY/27,1988/

N89223 001

/80MG/15ML/

/NASKA/

N80743 001

THEOPHYLLINE

TABLET; ORAL

QUIBRON-T
/+/BRISTOL/NIERS/

/300MG/

/N86556/001/
/AUG/22/1985/

N86556 001
AUG 22, 1985

/AB/

TABLET; ORAL
THEOPRIDAZINE HCL

/10MG/

/N88351/001/
/DEC/05/1983/

+ ROBERTS

300MG

N88351 001

/AB/

TABLET; ORAL
THEOPRIDAZINE HCL

/15MG/

/N88352/001/
/DEC/05/1983/

/THEOPHYLL-225/
/JOHNSON/RW/

/225MG/
225MG

/N84726/001/
N84726 001

/AB/

TABLET; ORAL
THEOPRIDAZINE HCL

/25MG/

/N88335/001/
/DEC/05/1983/

JOHNSON RW

225MG

N84726 001

/AB/

TABLET; ORAL
THEOPRIDAZINE HCL

/50MG/

/N88322/001/
/DEC/05/1983/

TABLET; CHEMABILE; ORAL/
/THEOPHYLL/
/JOHNSON/RW/

/100MG/

/N86506/001/
/SEP/12/1985/

3 PAR

/100MG/

/N88480/001/
/DEC/29/1983/

JOHNSON RW

100MG

N86506 001

3

10MG

N88480 001

JOHNSON RW

100MG

N86506 001

3

15MG

N88336 001

JOHNSON RW

100MG

N86506 001

3

25MG

N88336 001

TABLET, EXTENDED RELEASE; ORAL

QUIBRON-T/SR

/BC/ /BRISTOL/NIERS/

/300MG/

/N87563/001/
/JUN/21/1983/

/AB/ /ZENITH/

/100MG/

/N88480/001/
/DEC/29/1983/

BC ROBERTS

300MG

N87563 001

3

100MG

N88480 001

THEOPHYLLINE SODIUM GLYCINATE

/ELIXIR; ORAL/
/SYNOPIRATE/
/CENTRAL/PHARMS/
3 CENTRAL PHARMS

/EQ/165MG/BASE/15ML/
EQ 165MG BASE/15ML

/N86333/008/
N86333 008

> DLT >
> DLT >
> ADD >
> ADD >

INJECTABLE; INJECTION
/THIO-TEPA/
/LEDERLE/
THIOTEPA

/15MG/VIAL/

/N11683/001/
N11683 001

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL
/BEL/MAR/

3 BEL MAR

/100MG/ML/
/200MG/ML/
100MG/ML
200MG/ML

/N80718/001/
/N80712/001/
N80718 001
N80712 001

INJECTABLE; INJECTION
TICAR

EQ 20GM BASE/VIAL
EQ 30GM BASE/VIAL

N11683 001

AP FUJISAWA

AP /LYPHOMED/
AP /STERIS/
AP /STERIS/

/100MG/ML/
/200MG/ML/
100MG/ML
200MG/ML

/N80556/001/
/N80571/002/
/N83534/002/
N80556 001
N80571 002
N83534 002

+ SMITHKLINE BEECHAM

EQ 20GM BASE/VIAL
EQ 30GM BASE/VIAL

N50497 004
N50497 005
APR 04, 1984

+ STERIS

ICLOPIDINE HYDROCHLORIDE

TABLET; ORAL
TICLID
+ SYNTEX

250MG
125MG
/250MG/

N19979 002
OCT 31, 1991
N19979 001
MAR 24, 1993
/N19979/002/
/05/21/1991/

> ADD >
> ADD >
> DLT >
> DLT >

AEROSOL, METERED; INHALATION
AZHACORT
+ RHONE POULENC RORER 0.1MG/INH
/+/ /0.25MG/INH/

N18117 001
APR 23, 1982
/N18117/001/
/APR/23/1982/

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE
NOVOPHARM

AB 5MG
AB 10MG
AB 20MG

N72648 001
JUN 16, 1993
N72649 001
JUN 16, 1993
N72650 001
JUN 16, 1993

CREAM; TOPICAL
TRIAMCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.025%/
/AT/ /0.1%/
/AT/ /0.5%/
0.025%
0.1%
0.5%

/N87992/001/
/JUL/07/1983/
/N87991/001/
/JUL/07/1983/
/N87992/001/
/JUL/07/1983/
N87990 001
JUL 07, 1983
N87991 001
JUL 07, 1983
N87992 001
JUL 07, 1983

TOLMETIN SODIUM

CAPSULE; ORAL
TOLMETIN SODIUM
MYLAN

AB EQ 400MG BASE

N73393 001
MAY 27, 1993

OINTMENT; TOPICAL
TRIAMCINOLONE ACETONIDE
BARRE 0.5%
/AT/ /NASKA/ /0.5%/
/AT/ /PHARMADERM/ /0.025%/
/AT/ /0.1%/
0.025%
0.1%

N89913 001
DEC 23, 1988
/N89913/001/
/DEC/23/1988/
/N88692/001/
/AUG/05/1984/
/N88690/001/
/AUG/05/1984/
N88692 001
AUG 02, 1984
N88690 001
AUG 02, 1984

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
TRAZODONE HCL
MUTUAL PHARM

AB 50MG
AB 100MG

N73136 001
MAR 24, 1993
N73137 001
MAR 24, 1993

TRETINOIN

/SNAB;/TOPICAL/
TRETIN-A/
/+/JOHNSON/RW/
JOHNSON RW

/0.05%/
0.05%

/N16921/002/
N16921 002

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
/TFP/
/GENEVA/

/EQ 10MG BASE/ML/

/N85787/001/
/APR/15/1982/

AA TRIFLUOPERAZINE HCL

EQ 10MG BASE/ML

N85787 001
APR 15, 1982

TRIFLUOPRAZINE HYDROCHLORIDE

TABLET; ORAL

/TFF/

/GENEVA/

AB

AB

AB

AB

/EQ 1MG BASE/

/EQ 2MG BASE/

/EQ 5MG BASE/

/EQ 10MG BASE/

/N85785/001/

/N85786/001/

/N85789/001/

/N85788/001/

EQ 1MG BASE

EQ 2MG BASE

EQ 5MG BASE

EQ 10MG BASE

N85785 001

N85786 001

N85789 001

N85788 001

TRIFLUOPERAZINE HCL

GENEVA

TRIFLUPROMAZINE

/SUSPENSION; ORAL/

/VESPIN/

/SQUIBB/

@ APOTHECON

/EQ 50MG HCL/5ML/

EQ 50MG HCL/5ML

/N11491/004/

N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

/TABLET; ORAL/

/VESPIN/

/SQUIBB/

/50MG/

/10MG/

/25MG/

10MG

25MG

50MG

@ SQUIBB

@

@

TRIHENYPHENIDYL HYDROCHLORIDE

TABLET; ORAL

TRIHENYPHENIDYL HCL

NYLOS TRADING

/TABLCAPS/

5MG

/5MG/

N85622 001

/N85622/001/

TRIOXSALEN

TABLET; ORAL

TRISORALEN

/ELDER/

ICN

/5MG/

5MG

/N12669/001/

N12697 001

TRIPLENNAMINE HYDROCHLORIDE

TABLET; ORAL

TRIPLENNAMINE HCL

/HEATHER/

@ HEATHER

NYLOS TRADING

/TABLCAPS/

/50MG/

50MG

50MG

/50MG/

/N83989/001/

N83989 001

N85412 001

/N85412/001/

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION

TUBOCURARINE CHLORIDE

/QUAD/

@ QUAD

3MG/ML

/N89442/001/

N89442 001

AUG 12, 1988

VALPROIC ACID

CAPSULE; ORAL

VALPROIC ACID

PHARMACAPS

250MG

N73484 001

JUN 29, 1993

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION

VANCOCIN HCL IN PLASTIC CONTAINER

+ LILLY

Eq 500MG BASE/100ML

N50671 001

APR 29, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION

VERAPAMIL HCL

MARSAM

2.5MG/ML

N72233 001

FEB 26, 1993

TABLET; ORAL

VERAPAMIL HCL

MATSON LABS

40MG

N72923 001

JUN 29, 1993

40MG

N72924 001

JUN 29, 1993

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE

FUJISAWA

/L-YPHOMED/

1MG/ML

/1MG/ML/

N89515 001

APR 29, 1987

/N89515/001/

/APR/29, 1987/

POWDER; ORAL

XYLO-PFAN

/AA/

/ADRIA/

AA SAVAGE

/25GM/BOT/

25GM/BOT

/N17605/001/
N17605 001

VITAMIN A PALMITATE

CAPSULE; ORAL

AFAXIN

@ STERLING

VITAMIN A

/WHARTON/

@ WHARTON

/ZENITH/

@ ZENITH

@

EQ 50,000 UNITS BASE

N83187 001

/EQ 50,000 UNITS BASE/

EQ 50,000 UNITS BASE

/EQ 50,000 UNITS BASE/

EQ 50,000 UNITS BASE

/EQ 50,000 UNITS BASE/

EQ 50,000 UNITS BASE

/EQ 50,000 UNITS BASE/

/N83665/001/

N83665 001

/N83665/001/

N83665 001

/N83190/001/

N83190 001

INJECTABLE; INJECTION

AQUASOL A

/ASTRA/

ASTRA

/VITAMIN A PALMITATE/

/BEL/MAR/

@ BEL MAR

/EQ 50,000 UNITS BASE/ML/

EQ 50,000 UNITS BASE/ML

/EQ 50,000 UNITS BASE/ML/

EQ 50,000 UNITS BASE/ML

/EQ 50,000 UNITS BASE/ML/

EQ 50,000 UNITS BASE/ML

/N06823/001/

N06823 001

/N80819/001/

N80819 001

MARFARIN SODIUM

TABLET; ORAL

COUMADIN

/DUPONT/

@ DUPONT

/+/

>_ADD_> BX DUPONT

>_ADD_> BX

>_ADD_> BX +

/N09218/013/

N09218 013

/N09218/013/

N09218 013

/N09218/007/

N09218 018

/N09218 007

XENON, XE-133

GAS; INHALATION

XENON XE 133

MEDI PHYSICS

@

10MCI/VIAL

20MCI/VIAL

N17687 002

N17687 003

/INJECTABLE; INJECTION/

/ZINC SULFATE/

/L-YPHOMED/

@ LYPHOMED

/EQ 1MG ZINC/ML

EQ 1MG ZINC/ML

/N19229/002/
N19229 002

/MAY/05, 1987/

MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL
NEOPAP
/ALCON/
POLYMEDICA

/1.20MG/
120MG
/N164401/001/
N16401 001

N20289 002
APR 26, 1993

CLOTRIMAZOLE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN COMBINATION PACK
+ SCHERING PLOUGH

1%:100MG

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
/ALUMINUM/HYDROXIDE/AND/MAGNESIUM/TRISILICATE/
/PENNEX/

/80MG;20MG/
80MG;20MG
/N89449 001/
N89449 001
NOV 27, 1987

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHENHYDRAMINE HCL
BARRE

12.5MG/5ML
/N45446/5ML/
/NASKA/

N70497 001
APR 25, 1989
/N70447/001/
/APR/25./1989/

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
HIBISTAT
/S/STUART/
+ ZENECA

/0.5%/
0.5%
/N18300 001/
N18300 001

/200MG/
/200MG/

/N72901/001/
/DEC/19./1991/
/N72903/001/
/DEC/19./1991/

TINCTURE; TOPICAL
HIBITANE
/S/STUART/
@ ZENECA

/0.5%/
0.5%
/N18049 001/
N18049 001

200MG
200MG
200MG

N71144 001
JAN 20, 1987
N72901 001
DEC 19, 1991
N72903 001
DEC 19, 1991

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ISOCOLOR
CIBA

8MG;120MG
/FISON/

/200MG/

/N71214/001/
/DEC/01./1986/

/FISON/

MAR 06, 1986
/N18747/001/
/MAR/06./1986/

/200MG/

/N71154/001/
/DEC/27./1987/
N71154 001
OCT 27, 1987

CLOTRIMAZOLE

CREAM; VAGINAL
CLOTRIMAZOLE
NMC

1%
N74165 001
JUL 16, 1993

/200MG/

N71214 001
DEC 01, 1986
/N71164/001/
/JAN/26./1987/

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL
LOPERAMIDE HCL
WATSON LABS

1MG/5ML

N73062 001
MAY 28, 1993

TABLET; ORAL
LOPERAMIDE HCL
NOVOPHARM

2MG

N73254 001
JUL 30, 1993

> ADD >
> ADD >

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/TABLET; ORAL/
/TRIPROSED/
/HALSEY/

/60MG; 2;.5MG/

/NOV 19; 002/
/MAY 01; 1984/

/TRIPROLIDINE/HCL/ AND /PSEUDOEPHEDRINE/HCL/
/CHELSEA/

/NOV 11; 002/
/JAN 26; 1984/

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
MONISTAT 7 COMBINATION PACK
+ ADVANCED CARE 2%; 100MG

N20288 002
APR 26, 1993

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE; ORAL/
/ACTIFED/

/BURROUGHS/MELLICOME/ /30MG; 2;.5MG/

/NOV 08; 001/
/JAN 15; 1985/

/SYRUP; ORAL/
/ACTIFED/

/BURROUGHS/MELLICOME/ /30MG; 5ML; 1;.25MG; 5ML/

/NOV 05; 003/
/NOV 26; 1982/

/TRIOFED/
/BARRE/

/30MG; 5ML; 1;.25MG; 5ML/

/NOV 15; 001/
/MAR 04; 1983/

/TRIPROSED/
/HALSEY/

/30MG; 5ML; 1;.25MG; 5ML/

/NOV 23; 002/
/MAR 30; 1984/

/TABLET; ORAL/
/ACTIFED/

/BURROUGHS/MELLICOME/ /60MG; 2;.5MG/

/NOV 06; 002/
/NOV 26; 1982/

/TRI-SUPP/
/NO/PHARM/

/60MG; 2;.5MG/

/NOV 04; 002/
/JAN 10; 1984/

/TRIPRODRINE/
/DANEURY/PHARMA/

/60MG; 2;.5MG/

/NOV 12; 001/
/JAN 20; 1983/

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
CUMULATIVE SUPPLEMENT NUMBER 7 / JULY '93

INDIUM¹¹¹ CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM

N/A

N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru July 1993]

NAME <i>Generic/Chemical</i> <i>TN= Trade Name</i>	INDICATION DESIGNATED	SPONSOR & ADDRESS <i>DD=Date Designated</i> <i>MA=Marketing Approval</i>
8-METHOXSALEN TN= UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
AMINOSALICYLATE SODIUM TN=	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
AMINOSIDINE TN= GABBROMICINA	TREATMENT OF TUBERCULOSIS.	UNIVERSITY OF ILLINOIS AT CHICAGO 833 SOUTH WOOD STREET M/C 886 ROOM 176 CHICAGO IL 60612 DD 05/14/93 MA / /
ANTI-THYMOCYTE SERUM TN= NASHVILLE RABBIT ANTI-THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
APOMORPHINE HCL INJECTION TN=	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
ATOVAQUONE TN= MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
ATOVAQUONE TN= MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W. JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /
COLFOSCERIL PALMITATE, CETYL ALCOHOL, TYLOXAPOL TN= EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR GENE TN=	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	KIM, SINIL M.D. UCSD CANCER CENTER/0812 SAN DIEGO CA 92103 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT, INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
INTERFERON BETA (RECOMBINANT HUMAN) TN=	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
LIPOSOMAL DAUNORUBICIN TN= DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
M TN=	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /
MONOCLONAL ANTIBODY FOR IMMUNIZATION AGAINST LUPUS NEPHRITIS TN=	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
MONOLAURIN TN= GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC. 371 BEL MARIN KEYS, SUITE 210 NOVATO CA 94949 DD 04/29/93 MA / /
NITRIC OXIDE TN=	TREATMENT OF PRIMARY PULMONARY HYPERTENSION IN THE NEWBORN.	ANAQUEST, INCORPORATED 110 ALLEN ROAD LIBERTY CORNER NJ 07938 DD 06/22/93 MA / /
PRIMAQUINE PHOSPHATE TN=	FOR USE IN COMBINATION WITH CLINDAMYCIN HYDROCHLORIDE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	STERLING WINTHROP INC. 90 PARK AVENUE NEW YORK NY 10016 DD 07/23/93 MA / /
PROTEIN C CONCENTRATE TN= PROTEIN C CONCENTRATE (HUMAN) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH CORP. 750 LEXINGTON AVENUE, 19TH FLOOR NEW YORK NY 10022 DD 04/22/93 MA / /
RII RETINAMIDE TN=	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 05/06/93 MA / /
RT TN=	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN= Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
ROQUINIMEX TN= LINOMIDE	TO PROLONG TIME TO RELAPSE IN LEUKEMIA PATIENTS WHO HAVE UNDERGONE AUTOLOGOUS BONE MARROW TRANSPLANTATION.	KABI PHARMACIA, INC. 800 CENTENNIAL AVENUE PISCATAWAY NJ 08855-1327 DD 07/01/93 MA / /
SECALCIFEROL TN= OSTEO-D	TREATMENT OF FAMILIAL HYPOPHOSPHATEMIC RICKETS.	LEMMON COMPANY 650 CATHILL ROAD SELLERSVILLE PA 18960 DD 07/26/93 MA / /
SOMATROPIN TN= BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /
SUCRALFATE TN=	TREATMENT OF ORAL MUCOSITIS AND STOMATITIS FOLLOWING RADIATION THERAPY FOR HEAD AND NECK CANCER.	FUISZ TECHNOLOGIES, LTD. 3810 CONCORDE PARKWAY, SUITE 100 CHANTILLY VA 22021 DD 07/15/93 MA / /
THALIDOMIDE TN=	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /
TRETINOIN TN= TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN I TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM ³ .	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN II TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM ³ .	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
VASOACTIVE INTESTINAL POLYPEPTIDE TN=	TREATMENT OF ACUTE ESOPHAGEAL FOOD IMPACTION.	RESEARCH TRIANGLE PHARMACEUTICALS 200 WESTPARK CORPORATE CENTER DURHAM NC 27713 DD 06/23/93 MA / /

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W. JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
INTERFERON BETA, RECOMBINANT HUMAN TN=BETASERON	TREATMENT OF MULTIPLE SCLEROSIS.	CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE CA 94608 DD 11/17/88 MA 07/23/93

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME <i>Generic/Chemical</i> <i>TN- Trade Name</i>	INDICATION DESIGNATED	SPONSOR & ADDRESS <i>DD-Date Designated</i> <i>MA-Marketing Approval</i>
---	------------------------------	---

Orphan Drug Approvals

LEUPROLIDE ACETATE
TN= LUPRON INJECTION

TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.

TAP PHARMACEUTICALS, INC.
2355 WAUKEGAN ROAD
DEERFIELD IL 60015
DD 07/25/88 MA 04/16/93

LEVOMETHADYL ACETATE
HYDROCHLORIDE
TN=ORLAAM

TREATMENT OF HEROIN ADDICTS SUITABLE FOR MAINTENANCE ON
OPIATE AGONISTS.

BIODEVELOPMENT CORPORATION
1300 NORTH 17TH STREET, SUITE
300
ARLINGTON VA 22209-2306
DD 01/24/84 MA 07/09/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO JULY 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

DRUG NAME (DOSAGE FORM)

DATE

REVISED DATE

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

BUMETANIDE (TABLET)	APR 23, 1993
CEFACTOR (CAPSULE AND SUSPENSION)	APR 23, 1993
CAPTOPRIL (TABLET)	MAY 13, 1993
CHOLESTRYRAMINE (POWDER)	JUL 15, 1993
GLIPIZIDE (TABLET)	APR 23, 1993
GLYBURIDE (TABLET)	APR 23, 1993
GUANABENZ ACETATE (TABLET)	APR 23, 1993
INDAPAMIDE (TABLET)	APR 23, 1993
KETOPROFEN (CAPSULE)	APR 23, 1993
PINDOLOL (TABLET)	APR 23, 1993
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993
TRIAZOLAM (TABLET)	DEC 24, 1992

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
---------------------------------	------------------------------	---------------	------------	------------------------	--------

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF AND SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES

NEW DOSING SCHEDULE

D-20 SINGLE 32MG DOSE

REFERENCES

NEW INDICATION

I-87 RENAL IMAGING AGENT FOR USE IN CHILDREN
 I-88 MANAGEMENT OF ENDOMETRIOSIS
 I-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
 I-90 INTENSIVE CARE UNIT SEDATION
 I-91 MONOTHERAPY USE FOR HYPERTENSION
 I-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
 I-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS

REFERENCES

PATENT USE CODE

U-74 METHOD OF PROVIDING HYPNOTIC EFFECT
 U-75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
 U-76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
 U-77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
 U-78 ULCERATIVE COLITIS

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
18473 001	ALBUTEROL; VENTOLIN	4851229	JUN 14, 2005		I-93	JUL 20, 1996
>ADD>						
19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4777049	OCT 11, 2005		I-93	JUL 20, 1996
19604 001	ALBUTEROL SULFATE; VOLMAX	4751071	JUN 14, 2005			
		4851229	JUN 14, 2005			
		4777049	OCT 11, 2005			
19604 002	ALBUTEROL SULFATE; VOLMAX	4751071	JUN 14, 2005			
		4517199	MAY 14, 2002	U-15		
20258 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	4219559	AUG 26, 1999		NS	DEC 23, 1995
19402 001	ASTEMIZOLE; HISMANAL	4522807	JUN 11, 2002		NCE	DEC 29, 1993
20045 001	AVOBENZONE; SHADE UVAGUARD	4387089	JUN 07, 2002		NC	DEC 07, 1995
19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
20186 001	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63		
20186 002	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63		
20186 003	BISOPROLOL FUMARATE; ZIAC	4258062	MAR 24, 1998	U-63		
>ADD>						
20210 001	CISAPRIDE MONOHYDRATE; PROPULSID					
>ADD>						
20210 002	CISAPRIDE MONOHYDRATE; PROPULSID					
20229 001	CLADRIBINE; LEUSTATIN					
19287 001	DIAZEPAM; DIZAC					
18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		ODE	DEC 22, 1999
18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		ODE	DEC 22, 1999
18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		NCE	DEC 31, 1996
19680 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008		NCE	DEC 31, 1996
19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008		NCE	DEC 31, 1996
19794 002	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008		NCE	DEC 31, 1996
18651 001	DRONABINOL; MARINOL				ODE	FEB 26, 2000
18651 002	DRONABINOL; MARINOL				ODE	FEB 26, 2000
18651 003	DRONABINOL; MARINOL				ODE	FEB 26, 2000
19616 004	ENOXACIN; PENETREX				NDF	JUN 18, 1996
19616 005	ENOXACIN; PENETREX					
20164 001	ENOXAPARIN SODIUM; LOVENOX	4359578	NOV 16, 2001			
		4359578	NOV 16, 2001			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
>ADD>						
20189 001	FELBAMATE; FELBATOL	4316839	MAR 03, 2003		NCE	JUL 29, 1998
>ADD>		43174081	FEB 02, 2001		NCE	JUL 29, 1998
>ADD>		4194009	APR 19, 1994		NCE	JUL 29, 1998
20073 001	FLUMAZENIL; MAZICON	4018895	APR 19, 1994		NCE	DEC 20, 1996
18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4215113	JUN 06, 2000	U-12		
		4687659	AUG 18, 2004	U-64		
				U-76		
20068 001	FOSCARNET SODIUM; FOSCAVIR				NCE	SEP 27, 1996
20123 001	GADODIAMIDE; OMNISCAN				NCE	JAN 08, 1998
17783 003	GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994
19726 001	GOSERELIN ACETATE; ZOLADEX				1-88	FEB 02, 1996
19032 001	GUANFACINE HYDROCHLORIDE; TENEX				1-91	MAY 11, 1996
19032 002	GUANFACINE HYDROCHLORIDE; TENEX				1-91	MAY 11, 1996
19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NDF	DEC 07, 1995
18538 002	INDAPAMIDE; LOZOL				NCE	JAN 11, 1994
					NDF	DEC 07, 1995
					NS	APR 29, 1996
>ADD>					NCE	JUL 06, 1993
19710 005	IVERSOL; OPTIRAY 350				1-48	JUL 27, 1996
20215 001	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
19084 001	KETOCONAZOLE; NIZORAL	4335125	JUN 15, 1999		NS	JUN 30, 1996
19700 001	KETOROLAC TRONETHAMINE; ACULAR	5110493	MAY 05, 2009	U-75	1-30	JAN 27, 1996
		4454151	JUN 12, 2001	U-75	NCE	NOV 30, 1994
		4089969	MAY 16, 1997	U-75	NDF	NOV 09, 1995

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20263 001	LEUPROLIDE ACETATE; LUPRON	4917893	MAR 24, 2004		NP	APR 16, 1996
		4849228	JUL 18, 2006			
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4005063	JAN 25, 1996		ODE	APR 16, 2000
		4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4005063	JAN 25, 1996		ODE	APR 16, 2000
		4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4005063	JAN 25, 1996		ODE	APR 16, 2000
		4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
18948 001	LEVOCARNITINE; CARNITOR	4005063	JAN 25, 1996		ODE	APR 16, 2000
18948 002	LEVOCARNITINE; CARNITOR	4917893	MAR 24, 2004			
20315 001	LEVOMETHADYL ACETATE HYDROCHLORIDE; ORLAAM	4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
		1-86	DEC 16, 1995		1-86	DEC 16, 1995
		ODE	DEC 16, 1999		ODE	DEC 16, 1995
		1-86	DEC 16, 1995		1-86	DEC 16, 1995
		ODE	DEC 16, 1999		ODE	DEC 16, 1999
		NCE	JUL 09, 1998		NCE	JUL 09, 1998
		ODE	JUL 09, 2000		ODE	JUL 09, 2000
		1-92	JUN 09, 1996		1-92	JUN 09, 1996
		1-92	JUN 09, 1996		1-92	JUN 09, 1996
		1-92	JUN 09, 1996		1-92	JUN 09, 1996
		1-92	JUN 09, 1996		1-92	JUN 09, 1996
		4374829	DEC 30, 2001			
		4374829	DEC 30, 2001			
		4374829	DEC 30, 2001			
		4374829	DEC 30, 2001			

>ADD>
>ADD>

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19777 001	LISINAPRIL; ZESTRIL	4374829	DEC 30, 2001		1-92	JUN 09, 1996
19777 002	LISINAPRIL; ZESTRIL	4374829	DEC 30, 2001		1-92	JUN 09, 1996
19777 003	LISINAPRIL; ZESTRIL	4374829	DEC 30, 2001		1-92	JUN 09, 1996
19777 004	LISINAPRIL; ZESTRIL	4374829	DEC 30, 2001		1-92	JUN 09, 1996
19777 005	LISINAPRIL; ZESTRIL	4374829	DEC 30, 2001		1-92	JUN 09, 1996
20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE	FEB 21, 1997
19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE	APR 12, 1998
20049 001	MESALAMINE; PENTASA	4496553	JAN 29, 2002	U-78	NP	MAY 10, 1996
20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 2000		NCE	FEB 13, 1995
>ADD>		4282251	AUG 04, 1998		NCE	MAR 01, 1993
20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
20066 001	NICOTINE POLACRILEX; NICORETTE DS	4892741	JAN 09, 2007		NCE	JAN 13, 1994
20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
19921 001	OFLOXACIN; OCUFLOX	4382892	MAY 10, 2000			
20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996
20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	FEB 01, 1997	U-53		
20014 001	PIRIBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004			
19795 001	PODOFILOX; CONDYLOX					
19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	DEC 13, 1995
19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NCE	OCT 31, 1996
19627 001	PROPOFOL; DIPRIVAN				NE	SEP 23, 1994
50689 001	RIFABUTIN; MYCOBUTIN				I-90	MAR 08, 1996
19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		ODE	DEC 23, 1999
19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
20134 001	STRONTIUM CHLORIDE, SR-89; METASTRON	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
19050 001	SUFENTANIL CITRATE; SUFENTA				MR	JUN 18, 1998
					1-89	MAR 19, 1996
20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 28, 2006	U-72		MAR 19, 1996
19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				1-87	NOV 27, 1995
20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
18163 003	TEMAZEPAM; RESTORIL	5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
		4051141	SEP 27, 1996		NCE	OCT 31, 1996
19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
		4051141	SEP 27, 1996		NCE	OCT 31, 1996
18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
		4215104	JUL 29, 1997			
18776 003	VECURONIUM BROMIDE; NORCURON	4297351	OCT 27, 1998			
		4237126	DEC 02, 1997			
19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	APR 30, 1994
19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997
					NCE	DEC 16, 1997

>ADD>
>ADD>

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
 PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19862 001	INDIUM 111 CHLORIDE; INDICLOR				NCE	DEC 29, 1997
841207 001	PENTASTARCH 10% IN SODIUM CHLORIDE 0.9%; PENTASSPAN	3911138	OCT 07, 1994	ODE	ODE	MAY 19, 1994
860909 001	PERFLUORODECALIN; FLUOSOL	4252827	FEB 24, 1998	NCE	NCE	DEC 26, 1994
900278 001	SATUMOMAB PENDETTIDE; ONCOSCINT			ODE	ODE	DEC 29, 1999

Library Use Only

ST. LOUIS COLLEGE OF PHARMACY



3 2201 90036 5061

RM301.45 .A66 1993 Jul Suppl

Approved drug products with
therapeutic equivalence

C:355661 M:174736 O:12937927

Library Use Only